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The current study was designed to examine the effects of uridine on depressive 
symptoms and neuropsychological test performance in depressed youth with bipolar 
disorder. Participants included 20 adolescents diagnosed with bipolar depression between 
the ages of 13 and 21. Additionally, this study sought to compare depressed bipolar youth 
to an age- and gender-matched unaffected comparison group. Therefore, 10 unaffected 
comparison adolescents also participated in the study. Recruitment of participants took 
place between 2014-2015 at a university-based psychiatric hospital. All youth and their 
families provided consent to participate in the study and were administered a diagnostic 
clinical interview.  Mood was assessed weekly throughout the study using rating scales 
and neuropsychological tests were administered pre- and posttreatment. Bipolar 
participants were randomized to treatment with 500mg twice daily of uridine or placebo. 
Three participants were removed from the data analyses (2 in the uridine group and 1 in 
the placebo group) due to noncompliance.  
Results of the study demonstrated that uridine was tolerated and there were no 
serious adverse events. Three participants (33%) in the uridine vs. four participants (50%) 
in the placebo group showed reduced depression symptoms. However, there were no 
significant differences between the placebo and uridine groups on depression ratings 
from pre- to posttreament. Additionally, there were no differences in neurocognitive 
performance between the uridine or placebo groups from pre- to posttreatment.  
	   	   	  
	  
	   	   	   	   	  	  
iv 
Importantly, treatment with uridine did not have any negative effects on 
neurocognitive performance; however, these results did not suggest any 
neuropsychological benefits either. Bipolar participants showed more impairment in 
attention, executive functioning, and processing speed than unaffected comparison 
participants at baseline. Academic experiences for bipolar participants were different 
from comparison participants and included more academic difficulties, discontinuations, 
and transfers to new schools and programs. Participants who reported academic 
difficulties or received special education services performed lower on attention, working 
memory, executive functioning, and processing speed tasks. Without more subjects, no 
firm conclusions can be drawn from the current findings; however, these findings suggest 
a need for further research into uridine treatment. Treatment of adolescent bipolar 
disorder is complex and treatments specifically designed for youth are needed.  
 
	   	   	  
	  
	   	   	   	   	  	  




LIST OF TABLES……………………….………………………………………………vii 
 








Bipolar Disorder in Youth.….………......……………………………………………..3 
 Neuropsychological Deficits in Youth With Bipolar Disorder…..………….………...8            
Functional Impairments/Outcomes………….….…..……………………………..…14 
Treatments for Youth With Bipolar Disorder....…...………………………………...16 
Overview of Uridine Research………………………………………………….........18 
Uridine as a Treatment for Depression in Bipolar Disorder....……………………….21 






 Recruitment and Selection……………...………………………………………….....28  
  Setting and Procedures………………………….…………...……………………….33 
 Instruments……………………………………………………………………..…….36 
Interrater Reliability..………………………………………………………………...51 
Treatment Integrity…………………………………………………………………..52  
Design…………………………………………………………………………..……54 
      Data Analyses…….…...………………………….…………………...…………..…55 
 
III  RESULTS…………..………………………………………………...……………...59 
 
     Participant Characteristics…………………………………………………...………59 
     Results of Research Question 1…………………………………………...…………63 
Results of Research Question 2…..………………………………...………………..65
	   	   	  
	  
	   	   	   	   	  	  
vi	  
Results of Research Question 3..…...…………………………………………..……72 
Results of Supplemental Research Question 1…...………………………………….74 
Results of Supplemental Research Question 2…..…….…………………………….79 




    Major Research Findings.…………………………………………………...….……85 
     Safety and Tolerability…………………………………………………………….....93 
     Limitations and Future Research Considerations.……….…………………………..94 




A: PARENT PERMISSION, CONSENT, AND ASSENT FORMS..………………….101 
 





LIST OF TABLES 
 
Tables                          Page 
 
1. Treatments to Address Neuropsychological Deficits in Youth With BD……………25 
 
2. Measures for Study Eligibility……..……………………………..………………….37 
 
3. Study Measures………………………………………………………………………44 
 
4. Correlation Matrix for Baseline Composites….……………………………………..56 
 
5. Measures and Scoring by Domain Composite……..………………………………...58 
 
6. Participant Characteristics …………………………………………………………...60 
 
7. Secondary Diagnoses for Bipolar Participants……..………………………………...61 
 
8. Psychotropic Medications for Bipolar Participants..…………………………………62 
 
9. Means and Standard Deviations on Depression Measures ……………...…...………65 
 
10. Z-scores and Standard Deviations on Neuropsychological Domains for Participants 
With BD...………………………………….…….……………………...……….…..67 
 
11. Z-scores and Standard Deviations on Neuropsychological Domains for All 
Participants……………………………………….……………………...……….…..77 
 
12. Participant Educational Characteristics…….………………………………………..80 
 
13. Correlation Matrix for Academic Difficulties and Composites……………………...82 
 
14. Summary of Adverse Events for Participants ……………………………………….94 
 




LIST OF FIGURES 
 
Figures                         Page 
 
1. Recruitment and Selection of Participants………………………………...…………30 
2.  Eligibility Criteria to Participate in Study…………………………………………...32 
3. Study Procedures for All Participants………………………………………………..35 
4.  Mean Depression Composite Z-Scores Pre- and Posttreatment...…..……….………64 
5.  Mean Attention Composite Z-Scores Pre- and Posttreatment…...………..................66 
6.  Mean Executive Functioning Composite Z-Scores Pre- and Posttreatment.....……...69 
7.  Mean Working Memory Composite Z-Scores Pre- and Posttreatment.……………..70 
  8.  Mean Verbal Memory Composite Z-Scores Pre- and Posttreatment...…..………….71 
  9.  Mean Processing Speed Composite Z-Scores Pre- and Posttreatment.....…………..72 
 10. Mean CDRS-R Scores for Uridine and Placebo Groups Across Study One………..73 
11. Mean Z-Scores of Each Neurocognitive Domain for Bipolar and Comparison 




 I would like to thank my committee chair, Dr. Elaine Clark, who has devoted 
much of her time towards my training in graduate school. I am very grateful for her 
leadership and expertise that have assisted me through this process. I express my 
indebtedness to Dr. Douglas Kondo for his unrelenting dedication, knowledge, and 
encouragement that made this project possible. I am especially grateful for the guidance 
and support that I received from my research mentor, Dr. Perry Renshaw, to develop and 
conduct this dissertation study. Additionally, I would like to thank my dissertation 
committee members, Dr. Michael Gardner and Dr. Janiece Pompa, for their generous 
support and assistance in developing this dissertation.  
 I wish to acknowledge my family and friends for their love and support 
throughout my graduate school experience. Most importantly, I express my sincere 
gratitude to my husband, William Huff, whose unconditional love, patience, and 
understanding have sustained me throughout graduate school. 
  Finally, I would like to dedicate this dissertation to the participants with bipolar 
disorder and their families, in honor of their time and commitment to the study. I express 
my sincere appreciation to the participants and their families for their participation in this 






Approximately 1 to 2% of children and adolescents worldwide are affected by 
bipolar disorder (Youngstrom, Freeman, & Jenkins, 2009). Bipolar disorder (BD) in 
youth is characterized by abrupt mood swings of depression, mania, or hypomania 
(American Psychiatric Association, 2013). Youth with BD also experience euthymic 
episodes, which are states that are absent of manic/depressive symptoms. In addition, 
children and adolescents with BD often exhibit cognitive deficits that can interfere with 
their social functioning and academic performance and have been shown to have a 
significant, and negative, effect on long-term outcomes (Burdick, Goldberg, & Harrow, 
2010; Dickstein et al., 2004). Specifically, researches have found impairments in the 
areas of attention, executive function, working memory, verbal learning, spatial memory, 
and processing speed among youth with BD (Pavuluri, West, Hill, Jindal, & Sweeney, 
2009).  
It was initially believed that individuals with BD did not experience cognitive 
impairments during the euthymic state; however, researchers have found evidence of 
neuropsychological deficits during both a depressed and euthymic mood state (Basso, 
Lowery, Ghormley, & Bornstein, 2001). Neuropsychological deficits that persist across 
mood states have particular importance in terms of outcomes for individuals with BD 
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(Malhi et al., 2007). Nonetheless, there are no approved medication treatments for BD 
that have been shown to reduce the potential for cognitive impairment associated with 
drug therapy.  
Bipolar disorder (BD) in children and adolescents is understudied and treatments   
specifically designed specifically for youth are needed (Liu et al., 2011). Guidelines for 
treatment of youth with BD recommend using pharmacological intervention prescribed 
for adults (McClellan, Kowatch, & Findling, 2007). While medication is often the first 
line of treatment, it can have serious deleterious side effects. For example, lithium and 
antipsychotic medications used to treat BD have been associated with sedation, weight 
gain, headaches, dyskinesia, tics, tremors, and, when used by females, ovarian cysts 
(Blader & Kafantaris, 2007; Liu et al., 2011).  
In addition to concerns regarding safety, there are questions regarding the efficacy 
of medications for treating youth with BD. While lithium and antipsychotics have shown 
efficacy in treating youth with BD, at least 50% of adolescents experience symptom 
recurrence within 18 months (Birmaher et al., 2006). Some youth with BD are non-
responsive to medications, experience intolerable side effects, or require a combination of 
treatments to get desired effects (Pavuluri, 2008). All of these difficulties often lead to 
poor treatment adherence, which can further reduce the effectiveness of pharmacological 
intervention. A 12-month study following first hospitalization after a manic or mixed 
episode revealed that only 35% percent of adolescents with BD had full adherence to 
prescribed medications (DelBello, Hanseman, Adler, Fleck, & Strakowski, 2007). 
Furthermore, psychotropic medications and mood stabilizers may worsen  
neuropsychological impairments that youth with BD experience (Dias et al., 2012; 
Macqueen & Young, 2003).  
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One of the treatments that have been used during a depressed state of BD is 
uridine. Uridine is a naturally occurring pyrimidine nucleoside that is essential for RNA 
synthesis and is a critical element in the regulation of cellular energetics (Wurtman, 
Cansev, Sakamoto, & Ulus, 2010). Pyrimidines have been investigated in treating 
depressive disorders since the mid-1970s (Salvadorini, Galeone, Nicotera, Ombrato, & 
Saba, 1975). Nucleosides have been shown to be effective for treating disorders such as 
BD that are related to mitochondrial dysfunction (Saydoff et al., 2013). Following a 6-
week oral administration of 500 mg of uridine twice daily, 7 depressed adolescents with 
BD showed a 54% decrease in depression ratings on the Children’s Depression Rating 
Scale-Revised (CDRS-R) (Kondo et al., 2011).  
Furthermore, there are data that have shown uridine to increase cognitive and 
neuropsychological functioning in some patients with Alzheimer’s disease (Mi, van Wijk, 
Cansev, Sijben, & Kamphuis, 2013; Saydoff et al., 2013). It is, therefore, hypothesized 
that uridine, when used as a treatment for depression in adolescents with BD, can have 
neuropsychological benefits. The effects of uridine administration on neuropsychological 
test performance for individuals with BD have not yet been evaluated. The purpose of 
this study is to investigate effects of uridine in the treatment of BD on depressive  
symptoms and neuropsychological test performance in youth. 
 
Bipolar Disorder in Youth 
Historically, BD has been reported to occur in late adolescence and early 
adulthood. During the early 20th century, BD was reported by Emil Kraepelin to occur 
most frequently in youth ages 15 to 20 years of age (Kraepelin, 1921). Subsequent studies 
have shown that as many as 60% of adults with BD experienced symptoms before the age 
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of 20 and 10-20% of individuals with BD reported symptoms before the age of 10 
(Washburn, West, & Heil, 2011). Recently, there has been an increase in the diagnosis of 
children with “pediatric” BD who display severe irritability and mood dysregulation 
before the age of 10, leading to a debate about symptomatology and treatment of BD in 
youth (Parens & Johnston, 2010).  
From 1994-1995 to 2002-2003, there was a 4,000% increase in the diagnosis of 
BD in youth (Moreno et al., 2007). It is not known whether this increase was due to 
greater awareness of the disorder in children, a change in the diagnostic criteria from the 
DSM-III to the DSM-IV, influence of the pharmaceutical industry, or an actual increase 
in BD in youth (Parry & Levin, 2012). Regardless of the reason, the increase in pediatric 
BD has led to younger children being treated with medication, and subsequent concern 
regarding overmedication and adverse drug side effects.  
The American Psychiatric Association (APA) has attempted to address these 
issues in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, or 
the DSM-5. Specifically, recent changes to pediatric bipolar disorder in the DSM-5 have 
brought about questions regarding the future of diagnosis and treatment of BD in youth. 
The DSM-5 eliminated the diagnosis of pediatric BD and introduced a new diagnostic 
category called Disruptive Mood Dysregulation Disorder (DMDD).  DMDD is 
characterized by severe temper or aggressive outbursts, persistent irritable/negative mood 
that is observable by others between outbursts, and symptoms that have persisted for 12 
months prior to age 10. According to APA, the adoption of the DMDD diagnosis is an 
attempt to improve reliable and valid diagnosis and the treatment of children with mental 
health problems, and avoid over-diagnosis and overmedication of children (American 
Psychiatric Association, 2013). However, there are concerns regarding the limited scope 
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of research that preceded the new classification of DMDD, the lack of clinical 
guidelines/stability regarding diagnosis, and symptom overlap with other disorders; in 
particular, BD, Oppositional Defiant Disorder, and Conduct Disorder (Axelson et al., 
2012). Despite the removal of pediatric BD from the DSM-5, the diagnosis of BD still 
exists for individuals ages 10 and older. It should be noted that for the current study, the 
term “youth” will be used to describe individuals ages 13 to 21, not just 10 or older.  
 
Symptomatology and Course 
 Youth with bipolar disorder experience mood episodes of depression, 
mania/hypomania, and euthymia. Depression is defined as having a consistently 
depressed mood or loss of pleasure in daily activities for at least a 2-week period. The 
depressed mood impairs social and occupational functioning and is characterized by five 
or more of the following symptoms: depressed mood, loss of pleasure in activities, 
change in appetite, change in sleep, psychomotor retardation/agitation, fatigue, feelings 
of worthlessness/excessive guilt, inability to concentrate/indecisiveness, and/or recurrent 
thoughts of death (American Psychiatric Association, 2013).  
Mania is characterized by abnormally elevated or irritable mood for a period of at 
least 1 week with three of the following symptoms: grandiosity, decreased need for sleep, 
pressured speech, increase in goal-directed activity, racing thoughts, distractibility, and 
involvement in pleasurable activities. A severe episode of mania may cause impairment 
in occupational or social functioning, require hospitalization, or may include psychotic 
features. Bipolar I disorder is characterized by the occurrence of one or more manic 
episodes and often one or more depressive episodes. In contrast, hypomania is 
characterized by episodes of mania in which the duration is shorter and the mood episode 
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is usually less severe and does not cause serious impairment in functioning that requires 
hospitalization. Additionally, psychotic symptoms are not present during hypomania. 
Individuals who experience hypomanic episodes are diagnosed with bipolar II disorder. 
During a euthymic state, youth with BD do not experience symptoms of depression or 
mania/hypomania.  
Youth with bipolar disorder can switch from one mood episode to another. For 
example, approximately 60-70% of manic and hypomanic episodes occur immediately 
before or after a major depressive episode. If four or more mood episodes occur within a 
year, this is considered rapid cycling. The average age of onset for BD is 18 years of age. 
BD is a recurrent disorder and has a chronic course. More than 90% of individuals who 
experience a single manic episode will have additional manic episodes (American 
Psychiatric Association, 2013).   
Children and adolescents with BD experience different symptomatology than 
adults. For example, youth display more irritability and aggression while adults with BD 
tend to show more elation and grandiosity during mania (Safer, Magno Zito, & Safer, 
2012). BD that occurs in youth is worse than BD that occurs in adults with regard to 
mood symptoms and dysregulation. For example, the beginning of a manic episode for a 
child may be difficult to determine because the symptoms are different than those 
displayed by adults. Youth with BD display more symptoms of irritability during mania 
and they are more likely to abruptly to switch moods. However, as youth with BD 






Prevalence Rates and Comorbidities  
 The rates of BD are difficult to establish in youth; however, estimates suggest 
that between 1-2% of children worldwide have bipolar disorder (American Psychiatric 
Association, 2013). BD is more commonly diagnosed in high-income than in low-income 
countries (Ormel et al., 2008) and family history of BD is one of the strongest and most 
consistent risk factors. For first-degree relatives of individuals with BD, the risk of 
having BD is increased 10 times. Bipolar disorder is found equally in women and men, 
although gender appears to affect the type and number of mood episodes. The first mood 
episode in men is typically a manic episode, whereas women tend to experience a major 
depressive episode first. Overall, men are likely to have an equal number of manic and 
depressive episodes, while women experience more depressive episodes. Furthermore, 
rapid cycling is more common in women than in men (American Psychiatric Association, 
2013).  
Children and adolescents with BD often experience other psychological problems 
such as attention deficit hyperactivity disorder (ADHD), conduct disorder (CD), anxiety 
disorders, and substance use disorders. Anxiety disorders may include social phobia, 
panic attacks, and specific phobias. Studies have found a wide range in comorbidity rates 
for youth with BD in their samples, ranging from 11 to 75% for ADHD, 5 to 37% for 
CD, 12 to 56% for anxiety disorders, and 0 to 40% for substance use disorders (Pavuluri, 
Birmaher, & Naylor, 2005). Additionally, pediatric BD is found to be comorbid in 11% 
of children with Asperger’s disorder (Wozniak et al., 1997). Age appears to have an 
effect on comorbidity with different disorders. Substance abuse has been found to be 8.8 
times higher in adolescents than in children with BD (Wilens et al., 2004), while the rate 
of comorbid ADHD is higher in pediatric bipolar disorder than in adolescent bipolar 
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disorder (Findling et al., 2001). Individuals with BD in general are at a higher risk for 
suicidality; according to the American Psychiatric Association (2013), the rate of 
attempted suicide in BD ranges from 32 – 36%, and bipolar disorder may account for one 
quarter of all completed suicides. For individuals with bipolar II disorder, the lethality of 
attempts may be higher than in individuals with bipolar I disorder. 
 
Neuropsychological Deficits in Youth With Bipolar Disorder 
Neurocognitive problems in adults with BD have been recognized for over 50 
years. Interest in youth with BD has increased over the past 10 years, and a growing body 
of literature now documents different cognitive deficits occurring in youth compared to 
those observed in adults (Joseph, Frazier, Youngstrom, & Soares, 2008; Pavuluri et al., 
2005). Specifically, recent studies examining neurocognitive deficits in youth have 
identified deficits in attention, executive function, memory, and processing speed 
(Pavuluri et al., 2009). Neurocognitive functioning in youth with BD may have a large 
impact on academic and/or social performance, and affect further development. 
Therefore, several studies have investigated functioning and outcomes related to 
neuropsychological deficits (Burdick et al., 2010; Cahill, Green, Jairam, & Malhi, 2007; 
Malhi et al., 2007). Recent findings in these areas are described. 
 
Attention 
Youth with BD have been reported to demonstrate deficits in attention and 
vigilance (McClure et al., 2005). Several studies have investigated attentional capacity in 
youth with BD (Doyle et al., 2005; McClure et al., 2005; Pavuluri et al., 2009). Youth 
with BD performed more poorly in comparison to unaffected controls on the Continuous 
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Performance Test (CPT), a computerized test that is widely used to assess visual attention 
(Pavuluri, O'Connor, Harral, Moss, & Sweeney, 2006; Pavuluri et al., 2009). Doyle and 
colleagues (2005) used an auditory CPT with 57 participants with BD and 46 unaffected 
age- and gender-matched controls and demonstrated that participants with BD also 
performed significantly worse than controls on auditory CPT. 
 
Executive Functioning 
Another area of neuropsychological impairment in youth is executive functioning 
(EF). Outcomes for EF have traditionally been based on measures of set shifting, 
response inhibition, planning, and verbal fluency. The Wisconsin Card Sorting Task 
(WCST), the Trail Making Test (TMT-B), and the Intra-Dimensional/Extra Dimensional 
Set-Shift Subtest are measures of set shifting, or the ability to switch attention to different 
stimuli and show cognitive flexibility. Youth with BD performed worse on the WCST 
compared to both an unaffected control group (Meyer et al., 2004) and unaffected 
siblings (Doyle et al., 2009). Three studies have demonstrated set shifting deficits in 
youth with BD on the TMT-B (Bearden, Woogen, & Glahn, 2010; Pavuluri, O'Connor, et 
al., 2006; Pavuluri et al., 2009) and performance was more impaired for youth with BD 
than unaffected peers on the Cambridge Neuropsychological Test Automated Battery 
(CANTAB) Intra-Dimensional/Extra Dimensional Set-Shift Subtest (ID/ED shift) 
(Dickstein et al., 2007; Dickstein et al., 2004).  
Response inhibition, or suppression of an automatic action, is another aspect of 
executive function that has been found to be impaired in youth with BD (Doyle et al., 
2005). Youth with BD performed worse on a measure of response inhibition, the Stroop 
task, than unaffected controls (Doyle et al., 2005). The Controlled Oral Association Test 
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(COWAT) is often used to assess verbal fluency, or rapid retrieval of words from 
memory. Youth with BD demonstrated verbal fluency deficits when compared to 
unaffected controls on the COWAT (Pavuluri, O'Connor, et al., 2006; Pavuluri et al., 
2009). A 3-year follow-up study by Pavuluri and colleagues (2006) revealed impairment 
in the development of this aspect of executive functioning for youth with BD. Youth with 
BD showed improvements in executive functioning over time; however, performance 
lagged behind when compared to unaffected peers (Pavuluri, O'Connor, et al., 2006). 
 
Memory 
Three areas of memory have been found to be impaired in youth with BD: 
working memory, verbal memory, and visual-spatial memory. Of these areas, verbal 
memory appears to be most affected across all mood episodes in BD (Cavanagh, Van 
Beck, Muir, & Blackwood, 2002). Since learning is affected by the ability to organize 
and encode information into memory, verbal memory deficits may impair learning and 
academic performance in youth with BD. Youth with BD did not perform as well as 
unaffected controls on the California Verbal Learning Test - Child version (CVLT-C), a 
list-learning task that assess verbal memory (Pavuluri, O'Connor, et al., 2006; Pavuluri et 
al., 2009) or as well as unaffected controls and unaffected siblings on the CVLT-II 
(Doyle et al., 2009). In a study of 21 BD subjects, Glahn et al. (2005) found impaired 
verbal memory for BD I subjects; however, the scores of subjects with BD II and BD-not 
otherwise specified (NOS) did not differ from unaffected controls. 
Working memory deficits have also been investigated in youth with BD. The 
Wechsler Memory scales have been used to examine working memory using the 
Arithmetic, Digit Span, and Spatial Span subtests. Using the Wechsler Memory Scales, 
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youth with BD show working memory impairment when compared to controls (Pavuluri, 
O'Connor, et al., 2006; Pavuluri et al., 2009) as well as unaffected siblings (Doyle et al., 
2009). Dickstein et al. (2004) used the CANTAB spatial memory span with 21 BD youth 
and 21 unaffected controls and found impaired working memory for youth with BD.  
Visual-spatial memory is also affected in youth with BD. Deficits in visual-spatial 
memory were demonstrated by youth with BD compared to controls on performance on 
the Wide Range Assessment of Memory and Learning (WRAML) (Rucklidge, 2006) and 
the Spatial Working Memory Capacity Task (SCAP) (Bearden et al., 2010; Pavuluri, 
Schenkel, et al., 2006). Facial memory has also been shown to be impaired for youth with 
BD on the Test of Memory and Learning (TOMAL) (Olvera, Semrud-Clikeman, Pliszka, 
& O'Donnell, 2005). Results on the Penn Face Memory Test demonstrated impairment in 
youth with BD in the visual memory domain, due to worse performance on a face 
recognition task when compared to unaffected controls (Pavuluri et al., 2009).  
 
Processing Speed 
Processing speed, which is critical for learning, academic performance, and 
everyday functioning, is also affected in youth with BD. Impairments in processing speed 
have been assessed using the Digit Symbol/Coding subtests of the Wechsler scales. 
Youth with BD performed worse on these subtests of the WISC-III when compared to 
unaffected controls (Doyle et al., 2005; Doyle et al., 2009). Deficits in processing speed 
have also been identified in youth with BD using the TMT-A (Pavuluri et al., 2005; 
Pavuluri et al., 2009). A longitudinal study of youth with BD revealed that processing 
speed deficits are associated with poor global functioning and social adaptation (Burdick 
et al., 2010). 
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Neuropsychological Deficits in Mood States 
Recent research has explored neurocognitive deficits in BD youth, but few studies 
have controlled for mood state. Most of what is known about neuropsychological 
functioning in BD in different mood states is from research with adults. Evaluation of 
neurocognitive deficits during different mood episodes has revealed that impairment 
persists during euthymic states (e.g., Malhi et al., 2007; Robinson & Ferrier, 2006). 
Robinson and Ferrier, for example, demonstrated that subjects with BD experienced 
greater verbal memory impairment during mania, whereas Malhi et al. showed evidence 
of greater neuropsychological impairment during a depressed episode. This section 
describes the most recent findings regarding neuropsychological deficits of individuals 
with BD that are associated with each mood episode: depressive, manic, and euthymic.  
 During a depressive episode, adults with BD have demonstrated impairments 
across all neurocognitive domains (Malhi et al., 2007).  Deficits in sustained attention, set 
shifting, memory, and executive functioning have been associated with depressive 
episodes in BD (Trichard et al., 1995). Problems with verbal fluency, verbal recall, and 
recognition were also found in BD adults who were in a depressed state (Ali et al., 2001).  
Researchers using the Controlled Oral Word Association Test (COWAT) found that 
verbal fluency is worse for adults during a depressive episode than during an euthymic 
state (Martinez-Aran et al., 2004). Adults with BD have also demonstrated impaired 
problem solving, concept formation, and decision making during depressive episodes 
(Sweeney, Kmiec, & Kupfer, 2000). Poor psychosocial functioning was found to be 
associated with slow processing speed and reaction time during a depressive episode in 
adults with BD (Malhi et al., 2007). Several studies have compared bipolar and unipolar 
individuals during depressive episodes. Adults with unipolar and bipolar depression have 
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demonstrated memory and concentration impairments that may affect verbal learning (Ali 
et al., 2001). Moreover, adults with BD have impaired performance in verbal fluency and 
executive functioning compared with adults with unipolar depression (Borkowska & 
Rybakowski, 2001).   
Few studies have been conducted on individuals with BD during a 
manic/hypomanic episode; however, recent findings suggest that they are impaired in 
executive functioning. In particular, BD adults in a manic state have been found to 
experience difficulty with planning, set shifting, concept formation, and problem solving. 
Such individuals have demonstrated significant impairment on the CPT, which suggests 
difficulty with sustained attention and response inhibition (Strakowski et al., 2005). 
Reduced psychosocial functioning during hypomania has been associated with poor 
working memory and new learning (Malhi et al., 2007). Verbal memory and learning 
deficits during mania are thought to be related to an encoding deficit (Fleck et al., 2003). 
Spatial deficits and spatial memory impairments have been reported in adults with manic 
or mixed symptoms (Sweeney et al., 2000). Episodic memory deficits associated with 
mania have also been demonstrated in adult BD (McGrath, Chapple, & Wright, 2001). 
 During an absence of mood symptoms, a euthymic state, research indicates that 
neuropsychological impairments still persist, although they are not as severe as those that 
occur during episodes of mania or depression. During a euthymic state, adults with BD 
continue to show deficits in executive functioning and verbal memory (Malhi et al., 
2007).  McClure et al. (2005) demonstrated verbal memory deficits using the Test of 
Memory and Learning (TOMAL) delayed recall of stories. Adults with BD in a euthymic 
state have also shown difficulty with sustained attention (Ferrier, Stanton, Kelly, & Scott, 
1999). Despite good social adaptation in euthymic episodes, adults with BD may 
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experience visual-spatial recognition memory impairment (Cahill et al., 2007). During a 
euthymic state, BD adults made many perseveration errors on the Wisconsin Card Sort 
Test, which may represent a persistent deficit in cognitive flexibility (Cahill et al., 2007). 
Adults with BD may also have difficulties with problem solving. For example, adults 
with BD in a euthymic state relied on specific details rather than general information to 
solve problems, suggesting impairment in holistic processing (Sapin, Berrettini, 
Nurnberger, & Rothblat, 1987). 
Few studies have compared neuropsychological functioning across mood states; 
however, existing research indicates that impairment in attention, memory, and verbal 
fluency may persist across all mood episodes. Furthermore, the methodology used to 
compare neurocognitive functioning across mood states is complex and has limitations. 
Longitudinal studies have also shown that neuropsychological deficits may depend on the 
course of the illness. Burdick et al. (2010) found that the neuropsychological performance 
of adults with BD was correlated with affective symptoms, history of mood episodes, 
occupational functioning, and previous hospital admissions. Successive mood episodes 
that are severe, unstable, or long-lasting may further exacerbate cognitive impairments 
(Robinson & Ferrier, 2006).  
 
Functional Impairments/Outcomes 
Due to neuropsychological impairments, youth with BD may experience 
challenges that impact their ability to interact socially and perform to their full potential 
in school and work. Reading and writing difficulties are estimated to occur in about 42-
45%, and math difficulties are reported in about 30% of youth with BD (Pavuluri, 
O'Connor, et al., 2006).  Reading and writing impairments in youth with BD have been 
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found secondary to problems in attention and working/verbal memory, and may be 
impacted by executive functioning as well (Pavuluri, O'Connor, et al., 2006). 
Disturbances in attention in BD youth are associated with math difficulties. 
Neurocognitive impairments in BD youth in the areas of attention, memory, and 
processing speed have shown to been associated with dysfunctional social and vocational 
outcomes (Bearden et al., 2010). Processing speed deficits have been associated with 
poor global functioning and social adaptation (Burdick et al., 2010) and psychosocial 
functioning in BD has been correlated with poor executive functioning (Malhi et al., 
2007).  
When individuals with BD are reportedly functioning well, they often still 
describe difficulty with decision making that requires consideration of future 
consequences (Malhi et al., 2007). One common example is when individuals with BD 
discontinue the use of drug therapy after they see improvement in symptoms. Another 
finding associated with cognitive functioning and outcomes described the influence of 
verbal learning and memory impairment on occupational status for individuals with BD 
(Burdick et al., 2010). A longitudinal study by Burdick et al. (2010) of 33 participants 
with BD at 15 years following hospitalization found that an increase in the number of 
hospitalizations was associated with poor occupational status. These patients also had 
nearly three times as many mood episodes as patients with good work outcomes. 
Symptom management and treatment appear to be critical for improving long-term 






Treatments for Youth With Bipolar Disorder 
Pharmacological Treatments  
Current guidelines for treatment of youth with BD recommend medications used 
by adults with BD (McClellan et al., 2007).  These include lithium, mood stabilizers, 
anticonvulsants, and antipsychotics. Mood stabilizers and anticonvulsants that are used to 
treat adults with BD have also been used with youth (e.g., lamotrigine, valproate, 
carbamazepine, topiramate, and divalproex). Atypical antipsychotics that are used to treat 
BD in youth include olanzapine, quetiapine, risperidone, and aripiprazole. There are two 
recommended algorithms for pharmacological treatment of BD in youth based on the 
presence of psychosis. First, traditional mood stabilizers and atypical antipsychotics are 
suggested for youth with BD I, manic or mixed without psychosis. Combination therapy 
follows if there is partial or no response. Second, for BD with psychosis, combination 
therapy with a mood stabilizer and antipsychotic medication is recommended, and 
continued psychopharmacological treatment may be required to prevent relapse.   
To stabilize mood in BD, lithium is considered the gold standard and is often the 
first line of treatment. Although lithium has shown success in both short-term and long-
term treatment, it has been associated with cognitive side effects, including impairment of 
attention, short-term memory, and psychomotor skills. In a study of 46 BD patients, 
verbal memory and psychomotor speed were less impaired after 2 weeks of lithium 
discontinuation (Kocsis et al., 1993) when compared to their performance while taking 
the medication. Other studies have found contradictory results, and longitudinal studies 
of lithium use in BD suggest that cognitive dysfunction may not be directly affected by 
lithium, but rather by the duration of lithium exposure (Wingo, Wingo, Harvey, & 
Baldessarini, 2009). Reported beneficial effects associated with taking lithium include 
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reducing the risk of suicide (Tondo & Baldessarini, 2009) and prevention of Alzheimer’s 
disease (Nunes, Forlenza, & Gattaz, 2007). 
Despite their effectiveness at stabilizing mood, anticonvulsants have also been 
associated with memory, attention, and psychomotor impairments (Dias et al., 2012).  
Sedation, cognitive blunting, and neurotoxicity may occur with higher doses of some 
anticonvulsants, especially topiramate, valproate, and carbamazepine (Gualtieri & 
Johnson, 2006). Valproate has shown many negative effects on attention, psychomotor 
speed, memory, and learning (Gualtieri & Johnson, 2006). Carbamazepine is associated 
with impairments in memory, attention, and information processing (Gallassi et al., 
1988). Topiramate has been linked with deficits in attention, processing speed, verbal 
fluency, language, perception, and memory (Ketter, Wang, Becker, Nowakowska, & 
Yang, 2003). Conversely, lamotrigine is an anticonvulsant used during depressive 
episodes that has few cognitive side effects. In fact, lamotrigine treatment has shown to 
improve working memory and verbal memory in BD individuals. After 6 weeks of 
treatment, lamotrigine enhanced cortical functioning involved in memory and emotional 
regulation in BD individuals (Pavuluri, Passarotti, Mohammed, Carbray, & Sweeney, 
2010).   
Atypical antipsychotics have been used most frequently in combination with 
lithium or mood stabilizers. While they are also used as monotherapy, the majority of use 
is in combination with other medications. Atypical antipsychotics have shown more 
negative cognitive effects than lithium and anticonvulsants. Olanzapine has been 
successful for treatment in in all phases of BD, but it is associated with verbal memory 
impairment (Hammonds & Shim, 2009). Quetiapine has been associated with cognitive 
impairment and lethargy (Castren & Rantamaki, 2010). In euthymic BD individuals, 
 18
 
risperidone improved executive functioning (Bubser, Byun, Wood, & Jones, 2012).  
  The use of antidepressants with youth with BD is controversial, as many studies 
have shown no benefit to adding them to lithium (Dias et al., 2012). Antidepressants vary 
in their cognitive side effects, but no studies have examined the neuropsychological 
effects of antidepressants on BD. Tricyclic antidepressants and serotonin and 
norepinephrine reuptake inhibitors (SNRIs) have been associated with cognitive deficits, 
although selective serotonin reuptake inhibitors (SSRIs) have been suggested to have 
neuroprotective properties.  
In conclusion, many of the medications that children take to treat BD may affect 
cognition. Long-term pharmacological treatment can cause further cognitive impairment 
that may impair functional outcomes (Henin et al., 2007). Pharmacological treatment of 
youth with BD may require trying several different trials of medications until a successful 
combination can be found (Pavuluri, 2008). Furthermore, the side effects from 
medications can further complicate treatment compliance and adherence. Noncompliance 
with lithium treatment was associated with a 90% relapse rate in adolescents with BD. 
However, those adolescents with good treatment adherence still experienced 38% relapse 
18 months posthospitalization (Strober, Morrell, Lampert, & Burroughs, 1990).  
 
Overview of Uridine Research 
Since uridine is found in every human cell, its utilization and transport throughout 
the body and the brain have been extensively studied (Cansev, 2006). Recently, 
therapeutic uses of uridine have been examined in both human and animal research.  
Uridine has been investigated in its pure form, as a prodrug, and more frequently 
combined with other nutritional supplements.  
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Uridine has been investigated as the prodrug triacetyluridine (TAU) due to its 
bioavailability and ability to achieve higher uridine blood levels following oral 
consumption. Patients with cancer undergoing chemotherapy have received up to 6 grams 
of TAU four times daily with no adverse affects (Hidalgo et al., 2000). Research has 
investigated uridine-based compounds in individuals with diabetic neuropathy (Gallai, 
Mazzotta, Montesi, Sarchielli, & Del Gatto, 1992) and autism (Page & Moseley, 2002). 
Recently, a uridine compound has been created for the treatment of mitochondrial 
toxicities related to nucleoside reverse transcriptase inhibitor (NRTI) treatment in HIV 
patients (Walker & Venhoff, 2005). 
Uridine has also been investigated in animal models to test for possible 
neuroprotective effects in disorders such as Parkinson’s, Huntington’s, and Alzheimer’s 
diseases. In unmedicated patients with mild Alzheimer’s Disease, uridine improved 
memory performance (Mi et al., 2013). In animal models of Alzheimer’s disease, Saydoff 
et al. (2013) found that improvement in object recognition and social transmission of 
food preference improved motor behavior and reduced anxiety. Uridine and choline 
combined increased selective attention and spatial learning in a rodent model designed to 
test cognitive impairment (De Bruin, Kiliaan, De Wilde, & Broersen, 2003). 
Uridine can also be taken orally in the form of Cognizin, an over-the-counter 
supplement also known as citicoline or CDP choline. After citicoline is ingested, it is 
converted to choline and uridine in the gut. Studies have demonstrated that after taking 
CPD choline, blood uridine levels increase (Wurtman, Regan, Ulus, & Yu, 2000). 
Citicoline has been investigated in the treatment of vascular dementia, stroke, traumatic 
brain injuries, Parkinson’s disease, Alzheimer’s disease, and brain aging (Fioravanti & 
Buckley, 2006). Researchers have examined citicoline in the treatment of cognitive 
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impairment and there is evidence that it may play a role in improving memory and 
attention (Fioravanti & Buckley, 2006). For example, 30 patients with mild to moderate 
Alzheimer’s disease received 12 weeks of treatment with 1000 mg of citicoline or 
placebo. Results demonstrated that patients who received citicoline treatment had better 
cognitive performance on the Alzheimer’s disease Assessment Scale-Cognitive (ADAS-
cog) and increased brain bioelectrical activity of the occipital electrodes (Alvarez et al., 
1999).  
 Further, Cognizin has been reported to increase short-term memory and verbal 
memory in healthy adults (Spiers, Myers, Hochanadel, Lieberman, & Wurtman, 1996). 
After 6 weeks of Cognizin citicoline administration with healthy adults, there was an 
increase in cellular synthesis and cellular energy determined by increased PCr and PCr/Pi 
and PE in the ACC region of the brain (Silveri et al., 2008). Findings by McGlade et al. 
(2015) revealed that citicoline improved attention and motor speed performance in 
normal adolescent males in a trial of random assignment to 250 mg, 500 mg, or placebo 
daily for 4 weeks. Similar results of improved attentional performance were found with 
citicoline administration in a study of healthy adult women (McGlade et al., 2012). Both 
of these studies found that with daily oral administration of citicoline, performance on the 
CPT-II increased. Specifically, adult women made fewer omission and commission errors 
and adolescent males had improved detectability and lower commission errors.  
There are few known side effects following oral administration of uridine. Uridine 
is considered to be a safe dietary supplement with low risk for side effects and several 
potential benefits (e.g., increasing neuronal membrane synthesis) (Cansev, 2006). 
Further, there have been few reported adverse events even after administration of up to 
300 mg a day of uridine for up to 20 years (Webster, 1995). The only noted side effects 
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with oral uridine administration include diarrhea and abdominal cramps (van Groeningen, 
Peters, & Pinedo, 1993).  
 
Uridine as a Treatment for Depression in Bipolar Disorder 
Uridine is also currently undergoing investigation as a treatment for depressed 
adolescents with BD. Uridine occurs naturally and is present in most human cells; it can 
also be found in tomatoes, broccoli, and mother’s milk (Wurtman, 2008). Taken orally as 
a supplement, uridine is broken down in the stomach and specific uridine transporters 
facilitate circulation of uridine throughout the body (Cansev, 2006). Uridine is a 
pyrimidine nucleoside that is a critical element in the regulation of cellular energetics 
(Wurtman et al., 2010). Increasing the amount of uridine in the body may help facilitate 
the production of adenosine triphosphate (ATP) and increase brain pH (Jensen et al., 
2008). An increase in brain pH has been shown to increase mitochondrial functioning, 
reduce glutamate and lactic acid levels, and increase phosphocreatine levels. There is 
evidence that pyrimidines are effective in the treatment of mitochondrial disorders, such 
as BD (Saydoff et al., 2013). Specifically, uridine and uridine prodrugs have successfully 
treated mitochondrial disorders (Jensen et al., 2008).  
Triacetyluridine (TAU) is a uridine prodrug that is broken down into uridine after 
oral consumption. Naviaux (2000) investigated TAU in children with mitochondrial 
disorders and showed correction of renal tubular acidosis (RTA). Children with 
mitochondrial diseases were administered 2 grams of TAU three times daily for up to 
three years, and improvements in symptoms were noted (e.g., reduction in seizures, 
restoration of RTA) (Naviaux, McGowan, Barshop, Nyhan, & Haas, 1999). TAU has also 
shown to be effective in reducing symptoms of depression in adults. Jensen et al. (2008) 
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administered doses of up to 18 grams (6 gram doses 3 times daily) of TAU to 11 
depressed adults with BD for 6 weeks and found that patients with a 50% decrease in 
depressive symptoms had a significant increase in brain pH from baseline.   
Cytidine is another pyrimidine that is converted to uridine in the stomach. It has 
also has been investigated in the treatment of bipolar depression (Yoon et al., 2009). 
Results from a study by Yoon et al. administered placebo-controlled cytidine to 35 
participants with BD in a depressive episode for 12 weeks. Participants in the study 
received one gram of cytidine or placebo twice daily combined with valproic acid. 
Individuals with bipolar disorder who received cytidine were shown to experience a 
significant reduction in depressive symptoms early during treatment compared to 
individuals who received placebo. Additionally, Yoon et al. showed that participants 
receiving the cytidine had a greater reduction in glutamate/glutamine levels than bipolar 
individuals taking placebo. Utilizing supplements that target the glutamatergic system has 
been proposed as an encouraging treatment for bipolar disorder. Studies of cytidine and 
uridine have suggested that they possess antidepressant-like properties (Carlezon et al., 
2005; Carlezon et al., 2002) and Agarwal et al. (2010) suggested that uridine 
administration may be an effective treatment for individuals with BD. 
Studies of uridine with healthy adults have also indicated that uridine treatment in 
BD may be beneficial. Agarwal et al. (2010) showed that 7 days of 2 grams of placebo-
controlled uridine administration in 17 healthy adults increased total brain 
phosphomonoesters (PME). PME are necessary for the syntheses of phospholipid cellular 
membranes and are found in high concentrations in the developing brain (Bradler, 
Barrionuevo, Panchalingam, McKeag, & Pettegrew, 1991). It is important to note that 
individuals with BD have been shown to have decreased temporal lobe PME (Deicken, 
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Weiner, & Fein, 1995). 
Kondo et al. (2011) administered 500 mg of uridine twice daily to 7 depressed 
adolescents with BD during a recent open-label trial of uridine. Kondo and his colleagues 
found a significant decrease in the adolescents’ depression ratings after 6 weeks of 
treatment. Specifically, 7 depressed adolescents with BD demonstrated a 54% drop in 
depression ratings on the Children’s Depression Rating Scale-Revised (CDRS-R).  
Further, there is evidence that oral administration of uridine increases dopamine 
release (Wang, Pooler, Albrecht, & Wurtman, 2005). A 6-week animal study with 344 
aged rats demonstrated that after supplementation with the 2.5% uridine additive found in 
infant formulas, there was a significantly greater release in striatal dopamine (DA) when 
compared to aged rats that consumed a controlled diet. Increasing dopamine in the brain 
may ultimately affect mood and cognition as decreased dopamine activity has been 
associated with depressive symptoms in mood disorders (Diehl & Gershon, 1992). 
Increased dopamine has shown to be associated with improved attention, working 
memory, and performance on cognitive tasks (Aalto, Bruck, Laine, Nagren, & Rinne, 
2005). Therefore, uridine may benefit both mood symptoms and cognitive deficits in BD.  
There are few treatments that address neuropsychological deficits in BD, and 
none have been designed especially for children. Previous research has examined the 
neurocognitive effects of lamotrigine treatment in pediatric BD (Pavuluri et al., 2010) and 
memantine administration with BD adults (Iosifescu, 2013). After lamotrigine treatment 
for 14 weeks, participants with BD showed significant improvement in symptoms of 
depression and mania. Working memory and verbal memory significantly improved with 
lamotrigine treatment, and participants with BD were no longer significantly impaired in 
these areas relative to controls. Executive function also significantly improved during 
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treatment, but participant performance still lagged behind controls at follow-up (Pavuluri 
et al., 2010). Placebo-controlled memantine was administered to 12 participants with BD 
in a euthymic state for 12 weeks, and there was significant improvement in working 
memory, visual, and verbal memory. Improvement of cognitive deficits in asymptomatic 
individuals with BD was associated with increased neuronal viability (NAA levels). A 
summary of neuropsychological deficits in youth with BD and the current treatments and 
symptoms they have addressed are summarized Table 1. 
 
 Purpose of the Study 
Neuropsychological impairments are problematic for youth with BD. Deficits 
have been found in the domains of attention, executive functioning, memory, and 
processing speed (Horn, Roessner, & Holtmann, 2011). These deficits may greatly 
impact future social and vocational functioning for youth. Although current research has 
begun to acknowledge this issue, it is incompletely understood. Moreover, treatment for 
youth with BD typically entails the use of medications, some of which may further 
exacerbate neurocognitive problems.  The current study was designed to contribute to the 
limited scientific literature regarding treatments to improve depressive symptoms and 
neurocognitive functioning in pediatric BD. The current study investigated the effects of 
uridine on depressive symptoms and neuropsychological functioning in youth with BD. It 
is the first study to examine the cognitive effects of uridine, a nonpharmacological 
intervention in youth with BD. Based on the neurocognitive deficits experienced by 
youth with BD, especially during a depressive episode, the following research questions 






Table 1. Treatments to Address Neuropsychological Deficits in Youth With BD 
_____________________________________________________________________________________________________ 
    Domain                           Types of Deficits                                                                       Treatments  
 
Attention Attention and vigilance                  None  
Directing and sustaining attention   
 
Executive                 Switching attention to different stimuli (set shifting)              Lamotrigine significantly improved EF 
 Functioning          Suppression of an action (response inhibition)                          from baseline, but still lagged behind HC 
         Ability to switch thinking between multiple concepts              at follow-up  (Pavuluri et al., 2010)   
         (cognitive flexibility)          
 
Working Working memory                   Lamotrigine significantly improved WM 
Memory                                 (Pavuluri et al., 2010)    
     
                         Memantine significantly improved  
           working and visual memory 
              (Iosifescu, 2013)      
 
Verbal                       Ability to encode and recall verbal information             Lamotrigine significantly improved  
Memory                     verbal memory  (Pavuluri et al., 2010)     
       
Memantine significantly improved  
verbal memory (Iosifescu, 2013) 
          
Processing  Ability to process visual information                     None 






1. Are there significant differences in depressive symptoms after 6 weeks of placebo-
controlled uridine administration between adolescents with BD taking uridine (N = 
11) and those taking a placebo (N = 9)?  
2. Are there significant differences in performance on neuropsychological tasks (e.g., 
memory, attention, etc.) after 6 weeks of placebo-controlled uridine administration 
between adolescents with BD taking uridine (N = 11) and those taking the placebo (N 
= 9)?  
3. For adolescents with BD taking uridine, is there a quadratic effect of time on 
depressive symptoms? 
 
Supplemental Research Questions 
 The following research questions were intended to examine differences between 
unaffected comparison participants (N = 10) and participants with BD (N = 20). 
Additionally, they were generated to further examine differences between adolescents 
with BD and unaffected comparison participants.  
1. What are the differences in prestudy performance on neuropsychological tasks 
between nonaffected comparison subjects (N = 10) and depressed adolescents with 
BD (N = 20)?   
2. What are the differences in prior educational experiences between unaffected 
comparison participants and adolescents with BD? 
3. Is there a relationship between performance on neuropsychological tasks and 
academic difficulties for participants with BD? 









The present study was conducted concurrently with a placebo-controlled study of 
uridine administration at the University of Utah led by Douglas Kondo, Psychiatry 
Department faculty member in the School of Medicine. Kondo’s double-blind 
randomized controlled trial was intended to investigate the effectiveness of uridine as a 
treatment for youth with BD during a depressed mood state. That study was approved by 
the Institutional Review Board (IRB) at the University of Utah on 3/27/2013 (IRB 
#00060256 and will be referred to as Study One). Study One was a larger study focused 
on investigating depressive symptoms and changes in glutamate and glutamine in 
depressed adolescents with BD after 6-weeks of placebo-controlled uridine 
administration observed with magnetic resonance spectroscopy (MRS) neuroimaging. 
Study One was responsible for randomization and administration of uridine. 
The current study was a substudy of Study One to investigate both mood 
symptoms and neuropsychological performance during the placebo-controlled uridine 
trial. The current dissertation study was approved by the IRB on 4/28/2014 (IRB 
#00062904). Data used for the current analyses were drawn from both Kondo’s Study 
One and from mood measures, neuropsychological testing, and academic information
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Recruitment and Selection 
Participants in Study One were invited to participate in the current dissertation 
study. Two groups of participants were recruited, one with BD who were currently in a 
state of depression and had been depressed for 2 weeks or longer, and a comparison 
group that did not have any evidence of BD or other psychiatric diagnosis (i.e., disorder 
found in DSM-IV) or medical condition. It should be noted that participants with BD in 
Study One were recruited using radio advertisements, informational flyers, posting in 
local news letters, posting on a local website, and advertisements on Trax. Flyers were 
posted in the community and given to local mental health providers and clinics. Mental 
health providers and local clinics left brochures and flyers in waiting rooms and 
distributed them to interested clients with BD. The brochures and flyers contained 
information about the study, eligibility requirements, and contact information.   
Unaffected comparison (UC) participants were recruited for the current study in 
order to have age- and gender-matched controls for participants in Study One. Since 
studying adolescents with BD was the primary purpose of the current study, these 
participants were recruited first and began participation in the study. The unaffected 
comparison (UC) participants were recruited and began participation in the study 
procedures later. When the UC participants were initially recruited for Study One, flyers 
were placed around the local community. Recruitment for comparison participants was 
initially difficult because the UC participants received $125 compensation for 
participation in Study One, which included a diagnostic interview and a MRI brain scan. 
These participants were less interested in continuing in the current study, given the fact 
they were offered $25 for each study visit, for a total amount of $50. To increase 
participation in the current study, UC participants were scheduled for the baseline visit 
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of the current study the same day as the MRI scans for Study One.  
Interested participants contacted this primary investigator (PI) of the current study 
and completed a phone screening prior to being scheduled for a screening visit. The 
phone screening involved providing information about the study to potential participants 
and asking questions to see if participants would meet the eligibility requirements and 
comply with study protocol. A total of 177 people contacted the PI and were interested in 
participating in the study; 125 of those were interested in participating in the bipolar 
disorder (BD) group and 52 were interested in participating in what was termed the 
unaffected comparison (UC) group. Thirty-eight potential participants were scheduled for 
a screening visit. Twenty-six potential bipolar participants were screened to determine 
study eligibility, and 21 of those subjects met eligibility criteria. Twelve unaffected 
comparison participants were screened to determine eligibility criteria, of which 10 were 
found eligible to participate in the study. Seven individuals did not meet the eligibility 
criteria, 5 were in the bipolar group and 2 were in the UC group. Figure 1 outlines the 
recruitment and selection of participants in the current study. 
Participants with BD were males and females between the ages of 13 to 21 who 
were in a current depressive episode. All participants with BD met the DSM-IV-TR 
criteria for bipolar I, bipolar II, or bipolar-not otherwise specified (NOS) according to the 
SCID or the K-SADS. Dr. Kondo confirmed all diagnoses of BD and participant 
eligibility for Study One. Participants were required to be in Study One in order to be 
eligible to enroll in the current study. All bipolar disorders (bipolar I, II, or NOS) were 



































Figure 1. Recruitment and Selection of Participants. 
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Twenty-one participants with bipolar disorder consented to participate in the 
study. After consent was provided, 1 participant with BD withdrew from the study before 
attempting to complete any baseline measures given a lack of time or interest in 
participation. This participant, however, chose to stay enrolled in Study One.  Of the 20 
remaining participants with BD, 13 were female and 7 were male. The participants with 
BD ranged in age from 13 to 21. 
An age- and gender-matched nonaffected comparison group was included in the 
study in order to provide a comparison to adolescents with bipolar disorder. Ten 
unaffected comparison participants completed the study.  Participants in the comparison 
group had no current or previous diagnosed psychiatric disorder or substance use disorder 
as described in the DSM-IV-TR. Of the 10 unaffected comparison participants, 5 were 
male and 5 were female. Unaffected comparison participants ranged in age from 13-21. 
All participants had a standard score of 85 of higher on the Wechsler Abbreviated Scales 
of Intelligence-Second Edition (WASI-II; Wechsler, 2011). Exclusionary criteria used in 
the study included the following: 1) any comorbid medical, neurological, or psychiatric 
disorder that was not stable, or any current substance abuse; 2) participants who were in a 
manic mood state; 3) below- to low-average cognitive ability (i.e., FSIQ of 85 or below); 
4) suicidal behaviors, homicidal behaviors, or self-harm behaviors; 5) positive urine drug 
screen for cocaine unless due to appropriate use of a medication prescribed to the 
participant; 6) known hypersensitivity to study drug or excipients; and 7) participants 
who in the opinion of the investigators ( i.e., the current PI, the PI for Study One) were 
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Figure 2. Eligibility Criteria to Participate in Study. K-SADS = Kiddie Schedule for Affective Disorders and 
Schizophrenia for School-age Children; SCID = Structured Clinical Interview for DSM-IV; CDRS-R = Children’s 
Depression Rating Scale-Revised;  MADRS = Montgomery-Asberg Depression Rating Scale; YMRS = Young Mania 
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Setting and Procedures 
Interviews and assessment of study participants took place at the University 
Neuropsychiatric Institute (UNI).  All tests were administered to participants 
individually. Data were collected over a 12-month period from 2014 to 2015.  
Parent(s) and the adolescent were provided with a description of the study and given time 
to ask questions and consider their participation in the study. At least 1 parent provided 
permission for their adolescent to participate in the study, and adolescents aged 13-17 
provided informed assent, while individuals 18-21 years of age signed a consent form.  
After providing permission, assent, or consent to participate in the study, all 
participants were screened for study eligibility. Specifically, the PI for the current study 
or a psychiatrist at the Brain Institute working on Study One administered the structured 
clinical interview, the Kiddie Schedule for Affective Disorders and Schizophrenia, 
Present and Lifetime version (K-SADS-PL; Kaufman & Schweder, 2003). The K-SADS-
PL was given to the parent(s) and all adolescent participants between the ages of 13 and 
17. Participants who were 18 to 21 were directly administered the Structured Clinical 
Interview for DSM-IV (SCID I/P; First, Spitzer, Gibbon, & Williams, 1997).  
The Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski & 
Mokros, 1996) and the Montgomery-Asberg Depression Rating Scale (MADRS; 
Montgomery & Asberg, 1979) were used to assess depressive symptoms. The Young 
Mania Rating Scale (YMRS; Young, Biggs, Ziegler, & Meyer, 1978) was also 
administered to assess symptoms of mania. The Columbia Suicide Severity Rating Scale 
(C-SSRS; Posner, 2010) was administered to participants to assess suicidal ideation and 
self-harm. The Wechsler Abbreviated Scale of Intelligence-Second Edition (WASI-II; 
Wechsler, 2011) two-subtest version (Vocabulary and Matrix Reasoning) was 
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administered to all participants to determine if they had a score within the normal range. 
An ECG, blood, and urine samples from each participant were completed on each 
participant with BD by the principal investigator. Dr. Kondo obtained medical histories 
and conducted a physical exam.  
Once the adolescents with BD were determined to be eligible for study 
participation, they were randomly assigned to receive a placebo or 500 mg of uridine 
twice daily for 6 weeks. All participants with BD returned for weekly study visits and 
complete mood measures to ensure that they did not experience mood shifting throughout 
the study. After 6 weeks of placebo-controlled uridine administration, participants came 
back for a follow-up visit 2 weeks later. Unaffected comparison participants were not 
administered placebo-controlled uridine; however, they remained in the study for 6 weeks 
and completed mood and neuropsychological measures at baseline and final visits.  
Eligible participants completed neuropsychological measures and mood measures 
(described below) at the baseline and final study visits. Figure 3 diagrams the study 
procedures for all participants. The baseline study measures occurred within 1 week of 
the screening visit and prior to the placebo or the uridine administration. The final study 
visit was conducted approximately 6 weeks after the baseline study visit, prior to 
participants ending treatment with placebo or uridine. All participants completed all tests 
measures. At each weekly study visit, vital signs and information regarding side effects 
of placebo-controlled uridine, adverse events and concomitant medications were 
collected. Study staff also checked participants’ weekly logs (see treatment integrity 
section) for treatment adherence and recorded any missed doses of placebo-controlled 
uridine. Mood measures were administered at weekly visits to monitor mood. The final 
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 Participants with BD who completed all study procedures were compensated a 
total of $290. As previously described, for participating in Study One, they were paid 
$240 for completing screening, weekly study visits, follow-up, and two MRI scans. For 
the current study, participants were paid an additional $50, with $25 paid for completing 
the baseline study measures and $25 for completing the final study measures.  
Participants were assigned an alphanumeric study identification number to which 
all data in the study were linked. All personal identifiers were removed from the data in 
the analyses.  The data were stored in a locked closet at a secure location at the Brain 
Institute at the University of Utah. This is the location of the office of the primary 
investigator of the larger study, or Study One.  
The PI for the current study along with Dr. Kondo (the PI for Study One) 
administered all measures according to standardized procedures. During the assessments, 
participants were observed for signs of fatigue or distress and were offered opportunities 
for breaks. Scoring of all protocols and entering data into a secured database were 
completed by the Principal Investigator. 
 
Instruments 
Participants completed psychiatric and mood measures to determine eligibility for 
the current study (see Table 2). Specifically, participants completed a diagnostic 
interview and depression, mania, and suicide rating scales, which took about 90 to  
120 minutes to administer. Additionally, at the baseline visit, participants completed the 
Wechsler Abbreviated Scale of Intelligence-Second Edition (WASI-II) two-subtest version 




Table 2. Measures for Study Eligibility 
_______________________________________________________________________ 
    Domain           Measures                            Age Range_ 
 
Clinical Interview Kiddie Schedule for Affective Disorders                       13-17 
and Schizophrenia for School-age Children,  
Present and Lifetime Version  
(K-SADS-PL) 
 
Structured Clinical Interview for DSM-IV,             18-21  
Research Version, Patient Edition (SCID I/P) 
 
 
Cognitive Ability             Wechsler Abbreviated Scale of Intelligence-                 13-21 
Second Edition (WASI-II)   
 
Depression The Children’s Depression Rating             13-18 
Scale-Revised (CDRS-R)  
 




Mania Young Mania Rating Scale (YMRS)             13-21 
 
 
  Suicidal Ideation/         Columbia Suicide Severity Rating Scale                       13-21 




Measures for Study Eligibility 
Clinical Interview 
The Kiddie Schedule for Affective Disorders and Schizophrenia for School-age 
Children, Present and Lifetime version (K-SADS-PL; Kaufman & Schweder, 2003) is a 
structured clinical interview that assesses the current and lifetime presence and severity 
of psychopathology in children according to DSM-IV criteria. Consisting of 82 items and 
5 supplemental sections, it is administered to at least 1 parent and youth ages 13-17.  
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The K-SADS-PL requires completion of an introductory interview, diagnostic 
screening interview, and appropriate diagnostic supplements based on endorsement of 
current or past psychopathology. Information is gathered and summarized from all 
sources and current and lifetime ratings are made for each diagnosis. Symptoms are 
coded as not present, subthreshold, threshold, or no information. The K-SADS-PL has 
shown concurrent validity and test-retest reliability kappa coefficients in the excellent 
range (.77-1.0) for present and lifetime diagnoses of MDD, BD, anxiety disorder, conduct 
disorder, and oppositional defiant disorder (Ambrosini, 2000; Kaufman et al., 1997). 
Additionally, the K-SADS-PL has high sensitivity in diagnosing patients with BD. Each 
adolescent participant between the ages 13 and 17 and 1 of their parents completed the K-
SADS-PL with the PI’s (Huber and Kondo) to provide comprehensive information 
regarding current/past symptoms, medical/treatment history, family/school information, 
and current level of functioning.  
The Structured Clinical Interview for DSM-IV (SCID I/P; First et al., 1997) is a 
semistructured diagnostic interview used to assess current and past symptoms of 
psychopathology in individuals 18 and older. The SCID is the most frequently used semi-
structured interview in clinical research used to diagnose mental disorders included 
within the DSM-IV, including mood, anxiety, psychotic, substance use, somatoform, and 
adjustment disorders. There is an overview and screening questions for each module of 
the SCID. Sections of the SCID corresponding to diagnoses are skipped or completed 
based on answers to screening and entry questions in each section. All symptoms are 
rated as present, subthreshold, or absent for each disorder. Raters who have received 
appropriate training in administering the SCID have demonstrated a high level of test-rest 
reliability and accuracy in diagnosis (e.g., kappas of at least .75 on symptoms and 90% 
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accuracy in diagnosis) (Ventura, Liberman, Green, Shaner, & Mintz, 1998). The SCID 
was administered to participants between the ages of 18 and 21 by the PI to provide 
comprehensive information regarding current/past symptoms, medical/treatment history, 
family/school information, and current level of functioning.  
 
Cognitive Ability 
The Wechsler Abbreviated Scale of Intelligence-Second Edition (WASI-II; 
Wechsler, 2011) is a brief measure of cognitive ability that can be administered to 
individuals between the ages of 6 and 90. It consists of four subtests: Vocabulary, 
Similarities, Block Design, and Matrix Reasoning. Both the four-subtest version and two-
subtest version may be used to obtain a Full Scale IQ (FSIQ). When the four-subtest 
version is administered, a Verbal Comprehension Index (VCI) and a Perceptual 
Reasoning Index (PRI) are obtained. This version takes about 30 minutes to administer. 
The Vocabulary and Matrix Reasoning subtests can be combined to form the Full-Scale 
IQ-2 Subtests (FSIQ-2). The two-subtest version takes approximately 15 minutes to 
administer and provides an adequate estimate of general ability (Wechsler, 2011).  The 
WASI-II has excellent internal consistency, test-retest stability and concurrent validity 
with the WISC-IV and WAIS-IV (McCrimmon & Smith, 2013).  All participants were 
administered the two-subtest version of the WASI-II to confirm that their cognitive 
ability fell within the average- to above-average ranges (i.e., FSIQ of 85 or above).  
 
Depression 
 The Children’s Depression Rating Scale-Revised (CDRS-R; Poznanski & 
Mokros, 1996) is a clinician-completed semistructured interview to assess depression in 
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17 symptom areas, including those found in the DSM-IV. The CDRS-R takes about 20 
minutes to administer, and information about the child’s level of depression can also be 
obtained from parents and teachers. Each item is rated on a scale from 1 to 5, or 1 to 7. 
The lowest score (1) is for “no difficulties” and the highest score (5) or (7) is for “severe 
clinically significant difficulties.” All items are summed together for a total score, which 
is converted into a T-score. Interpretation is based on the range in which T-scores fall. 
For example, if a child obtains a T-score in the 65-74 range, a depressive disorder is 
“likely to be confirmed upon further questioning.” Interrater reliability for the CDRS-R 
was .74 for those familiar with it and .75 for those unfamiliar with it (Dowd, 2001). Item-
total correlations for interviewers familiar with the CDRS-R had a median of .62, 
whereas those unfamiliar with it had a median of .61. Test-retest reliability after 2 weeks 
was .80 (Stovall, 2001). Frazier et al. (2007) evaluated the factor structure of the CDRS-
R and found two separate factors, cognitive and somatic/affective symptoms. The CDRS-
R has been validated for use in child populations, but it has also been widely used in 
adolescent populations ages 13-17 years of age as a measure of depression for clinical 
trials. The CDRS-R was administered to all participants by the PI and Dr. Kondo to 
assess depressive symptoms throughout the study. 
The Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery & 
Asberg, 1979) is a 10-item clinician-administered rating scale for assessing the core 
symptoms and cognitive features of depression, which takes about 15 minutes to 
administer. Each item is rated on a scale from 0 to 6, with anchor points at ratings of 0, 2, 
4, and 6. All ratings on the MADRS are summed to generate a total score. Higher scores 
on the MADRS indicate an increase in the severity of depression. A score of 31 is 
considered “severe,” while 7 and under is considered “not depressed.” The MADRS has 
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high internal consistency, r = .95 (Galinowski & Lehert, 1995) and good interrater 
reliability, ranging from .89 to .97 (Montgomery & Asberg, 1979). The MADRS has 
been shown to be a valid instrument and to have high correlations (r = .90) with other 
depression rating scales such as the Hamilton Depression Rating Scale (Muller, 
Himmerich, Kienzle, & Szegedi, 2003). The MADRS was administered to all participants 
to assess depressive symptoms at baseline and at every study visit. The MADRS is 
typically used with adults 18 years and older, and since there were participants ages 18-
21 years old in the study, both the MADRS and CDRS-R were given to all participants to 
increase the reliability in depression ratings.  
 
Mania 
The Young Mania Rating Scale (YMRS; Young et al., 1978) is a clinician-
administered interview to assess symptoms of mania which takes about 20 minutes to 
administer. The YMRS is one of the most frequently used measures to assess symptoms 
of mania in youth and adults. It consists of 11 items and is based upon the individual’s 
report of symptoms in the past 48 hours and the interviewer’s behavioral observations. 
Each item has five levels of severity and the items are summed together for a total score. 
The YMRS total score may range from 0 to 60 and a score of 12 or less typically is 
characteristic of no symptoms of mania. The YMRS has excellent interrater reliability, (r 
= .93) and concurrent validity between the total score and independent global ratings 
(Young et al., 1978). The total YMRS score was also shown to have a high correlation 
with the number of days that patients were hospitalized. The YMRS was administered to 





The Columbia Suicide Severity Rating Scale (C-SSRS; Posner, 2010) is a 
clinician interview to assess recent and lifetime symptoms of suicidal ideation and self-
harm behavior in participants. When administering the C-SSRS, the intensity of any 
suicidal ideation (e.g., frequency, duration, controllability, etc.) is rated. Any reported 
suicidal behavior is also recorded, including the total number of attempts (aborted or 
interrupted) and any preparatory acts or behavior. For actual attempts, the lethality is 
rated. Posner et al. (2011) found that the C-SSRS has high sensitivity and specificity for 
suicidal behavior, and that the ideation and behavior subscales are sensitive to change 
over time. The C-SSRS has also shown strong convergent validity with other established 
suicidal ideation and behavior rating scales (e.g., Scale for Suicide Ideation, Suicidal 
Ideation Questionnaire-Junior). In a study with adolescents, the C-SSRS successfully 
predicted suicide attempts during the study (Posner et al., 2011). The C-SSRS Baseline 
version assesses most severe suicidality over the lifetime and current suicidality and was 
administered to all participants at the baseline. The C-SSRS Last Visit version was 
administered to all participants at each subsequent visit following the baseline visit to 
assess for changes in suicidal ideation or behavior. The risk of suicide in participants with 
BD was closely monitored during the study using the C-SSRS. No participants were 
withdrawn from the study due to an increase in suicidal ideation or behavior. 
 
Study Measures 
Mood Assessments  
The mood measures (described above) were administered to all participants at the 
screening visit and then used at each subsequent study visit to monitor mood symptoms 
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and mood episodes. No participants with BD switched to a manic episode during the 
study, and all scores on the YMRS were below 12. Additionally, mood symptoms for any 
of the participants with BD did not worsen to a point that the PI felt that a participant was 
unsafe or that he or she needed to be withdrawn from the study.  
 
Neuropsychological Assessments 
The neuropsychological tests assessed the following domains: 1) attention, 2) 
executive function, 3) working memory, and 4) verbal memory. The measures selected in 
these domains are widely used in both clinical and research settings and have been used 
in previous studies to assess neurocognitive functioning in youth with BD. These 
instruments were selected to collectively measure these domains of neuropsychological 
functioning, due to their good specificity in clinical and comparison groups and their high 
sensitivity in detecting changes from treatment. Neuropsychological tests listed in Table 
3, which took about 90 minutes to administer, were given to all participants on the first 
and final study visits.  
Attention. The Conners Continuous Performance Test-Second Edition (CPT-II; 
Conners, 2005; Deicken et al., 1995) is a computer-based program that measures 
attentiveness, impulsivity, sustained attention, and vigilance. On the CPT-II, participants 
respond to visual stimuli on the computer screen for varied presentation rates and 
intervals. Participants press the space bar whenever any letter other than the letter “X” 
appears on the screen. Instructions and a practice session are given before the CPT-II 
begins. The CPT-II displays letters for 250 milliseconds at 1-, 2-, and 4- second intervals 
for approximately 15 minutes. The CPT-II has shown good split-half reliability and 
validity, has been found to discriminate between clinical and nonclinical  
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Table 3. Study Measures. 
_______________________________________________________________________ 




  Depression The Children’s Depression Rating Scale-Revised (CDRS-R)  
Montgomery-Asberg Depression Rating Scale (MADRS) 
 
  Mania Young Mania Rating Scale (YMRS)      
 
  Suicidal Ideation/ Columbia Suicide Severity Rating Scale (C-SSRS)     
  Behavior    
 
NEUROPSYCHOLOGICAL ASSESSMENTS 
   
   Attention Conner’s Continuous Performance Test (CPT-II) 
 
   Executive Wisconsin Card Sorting Test - Computer Version 4 (WCST) 
   Functioning  D-KEFS Trails Making Test (Condition 4)  
 D-KEFS Color-Word Interference Test  (CWIT) 
 
 Working Memory Wechsler Intelligence Scale - 4th ed. (WAIS-IV)  
 Working Memory Composite  
 
   Verbal Memory California Verbal Learning Test – 2nd ed. (CVLT-II) 
 
 Processing Speed Wechsler Intelligence Scale - 4th ed. (WAIS-IV)  




   Academic          Academic Performance Rating Scale (APRS) - teacher 







youth, and is sensitive to medication changes in treatment (Riccio, Waldrop, Reynolds, & 
Lowe, 2001). All participants were administered the CPT-II at the baseline and final 
study visits. The variables of interest on the CPT-II were detectability, omission errors, 
commission errors, and variability. Detectability provides information on how well the  
examinee discriminates between targets and nontargets. Greater overall errors of 
detectability may indicate problems with accuracy and attention. Errors of omission 
indicate failure to respond to a target item and a high number might indicate 
distractibility. Commission errors are responses to nontarget items, and a high number 
may indicate impulsivity. Variability measures consistency of time in responding to 
targets over the length of the test.   
Executive functioning. The measures of EF were selected based on Banich’s 
(2009) integrative theory that neurobiological, psychological, and computation levels of 
the brain are all involved in executive processes. This model takes previous theories of 
EF into account and focuses on executive processes involved in updating, set-shifting, 
and inhibition. Assessments that were selected to measure these processes are widely 
used in both clinical and research settings, and have been used in previous studies 
assessing neurocognitive functioning in youth with BD and depressed youth. These 
instruments were selected as measures of EF due to their high sensitivity and specificity 
between clinical and comparison groups (Weyandt et al., 2012). 
The Wisconsin Card Sorting Test (WCST; Heaton, Chelune, Talley, Kay, & 
Curtiss, 1993) is a measure of executive functioning used to assess abstract concept 
formation and cognitive set-shifting that can be administered by an examiner or on the 
computer. In the WCST, participants are asked to categorize cards to one of four stimulus 
cards placed in front of them. The stimulus cards consist of various geometric forms that 
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have different shapes, colors, and numbers. The participant is given one card at a time 
and asked to sort it according to an underlying principle. The participant’s task is to learn 
the sorting rule. After each sorting attempt, the examiner provides corrective feedback so 
the participant may deduce the sorting principle. Once the criterion level of successful 
performance has been reached with a particular rule, the sorting rule changes and the 
participant must then decipher the new sorting principle. The sequence continues until all 
of the 128 cards are sorted, or six runs of 10 consecutive responses according to the 
correct principle are completed.  
The WCST has been normed with children and adolescents and can be used with 
individuals aged 6 ½ to 89. The total number of errors, perseveration errors, and 
conceptual responses are recorded.  Perseveration errors are the number of times that a 
participant responds according to a particular principle, despite being informed that the 
principle is incorrect. Conceptual responses are correct responses that occur in sequences 
of three or more. Interscorer reliability of the WCST ranges from .83 to 1.00. In a sample 
of children and adolescents, the standard error of measurement ranged from 7.94 to 11.91 
(Heaton, 1993). The WCST Computer Version 4-Research Edition was administered on 
the computer to all participants at baseline and final study visits. 
Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test, Number-
Letter Switching Condition (D-KEFS; Delis, Kaplan, & Kramer, 2001)  is an assessment 
of cognitive set-shifting. In the D-KEFS Trails Number-Letter Switching Condition, 
participants draw a line to connect circles with numbers and letters in an alternating 
fashion. Instructions are provided and each participant must successfully complete the 
sample item to demonstrate understanding before beginning the task. The D-KEFS Trails 
Number-Letter Switching Condition consists of 25 numbers and letters (numbers 1 to 13 
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and letters A to L) in circles on two adjacent pages. The participant is asked to connect 
the circles by alternating between numbers and letters in order as quickly as possible. The 
score is the time required in seconds to complete each trial and the number of errors 
made. The D-KEFS Trails Number-Letter Switching Condition was administered to all 
participants at the baseline and final study visits. 
D-KEFS Color-Word Interference Test (CWIT) (D-KEFS; Delis, Kaplan, & 
Kramer, 2001) is a measure of executive functioning that assesses inhibition. The CWIT 
takes about 5 minutes to administer and can be used with individuals aged 5 to 90. For 
the CWIT, participants are presented three traditional Stroop trials (color naming, color 
name reading, interference) and a fourth trial in which the participant switches between 
naming the color of ink and the conflicting color names. In the first trial of word reading, 
the participant is asked to read the names of color (e.g., red, blue) displayed in black ink. 
Participants are asked to read down each column and say the color name aloud. During 
the color trial, participants identify colors alone (rectangles printed in red, blue, or green). 
During the interference trial, participants are presented with the names of colors, which 
are printed in a differ color, and are asked to say the color of the ink the words are printed 
in rather than reading the color-words. The switching interference trial requires the 
participant to say the color of ink the color-words are printed in as in the previous 
interference trial, but if a word is in a box, the participant has to read the word and not 
say the color of ink.  This requires the participant to switch between naming the color of 
the ink and the conflicting color names. After each response, the experimenter determines 
the accuracy of the participant’s response. Each trial produces a score, based on the 
number of uncorrected and self-corrected errors and the total amount of time to complete 
each trial. Test-retest reliability scores range from .62 -.76 and the split-half reliability 
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ranges from.62-.86, with both types of reliability being moderate to high (Delis et al., 
2001). The CWIT was administered to all participants at the baseline and final study 
visits. 
Working memory. The Digit Span and Letter-Number Sequencing subtests from 
the Wechsler Adult Intelligence Scale – 4th Edition (WAIS-IV; Wechsler, 2008) were 
administered to all participants in the study to assess working memory. The WAIS-IV 
was used with all participants in the study without regard for the age limitation of this test 
(age 16 and up). The Digit Span subtest requires the participant to repeat numbers 
forward or backwards in the same order as read aloud by the examiner, or mentally 
arrange numbers in ascending order as read aloud by the examiner. The Letter-Number 
Sequencing subtest requires the participant to mentally arrange numbers in ascending 
order and letters in alphabetical order as read aloud by the examiner. Internal consistency 
of the WAIS-IV Working Memory Index was .94 (Wechsler, 2008b). Test-retest stability 
of the Working Memory Index for the WAIS-IV was .87, with an average of 3 weeks 
between testing.  
Verbal memory. The California Verbal Learning Test – Second Edition (CVLT-
II; Delis, Kramer, Kaplan, & Ober, 2000) was administered to all participants to assess 
verbal learning and memory at the baseline and final study visits. The CVLT-II is a word-
list learning task in which 16 words from List A are presented over five learning trials. 
Words are presented orally at the rate of one word per second and at the end of each trial, 
participants are asked to recall as many words from List A as possible. An interference 
word List B is given as a distractor, and then participants are asked to recall words from 
List A. Participants are cued with categories for the words (e.g., clothing, fruit, etc.) and 
are asked to recall as many words as they can in each category. After a 20-minute delay, 
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participants are asked to recall as many words from List A as possible. The final task is a 
recognition trial that presents words from List A with 16 distractor items. Participants 
have to make a forced choice (yes or no) if each word was in List A when asked. Scoring 
the CVLT-II includes the total number of words recalled during trials 1-5, the number of 
words recalled on delayed recall of List A, and recognition. These scores are converted 
into standardized scores. There is high test-retest reliability for immediate, delayed, and 
recognition trials of the CVLT-II (Delis et al., 2000). 
Processing speed. The Symbol Search and Coding subtests from the Wechsler 
Adult Intelligence Scale – 4th Edition (WAIS-IV; Wechsler, 2008) were administered to 
all participants to assess processing speed. The Symbol Search subtest requires the 
participant to visually scan a group of symbols and mark whether or not one of the 
symbols in the target group matches. The Coding subtest requires the participant to use a 
key and copy symbols that are paired with numbers within a specified time limit. 
Participants are allotted 2 minutes for each subtest. The total raw scores of the Processing 
Speed Index were computed and used in the analyses. Average test-rest reliabilities of the 
WAIS-IV Symbol Search and Coding were .80 and  .83 (Wechsler, 2008b). Internal 
consistency of the Processing Speed Index for the WAIS-IV was .90, and test-retest 
stability was .84. 
 
Academic Measures  
The Academic Performance Rating Scale (APRS; DuPaul & Rapport, 1991) is a 
rating scale for teachers to rate student academic skills and performance in the classroom 
within the past week. Higher scores indicate greater academic performance and success. 
The rating scale consists of 19 items on a 5-point scale. A principal components analysis 
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(PCA) revealed three factors for the APRS: academic success, impulse control, and 
academic productivity. The total APRS had adequate internal consistency (.95), as did the 
Academic Success (.94) and Academic Productivity (.94) subscales. The test-retest 
reliability was high for the total APRS (.95) and for Academic Success (.91) and 
Academic Productivity (.93) subscales for a 2-week period (DuPaul & Rapport, 1991). 
The APRS was completed by the teachers of 2 participants with BD in the current study. 
The Behavior Assessment System for Children, Second Edition (BASC-2; 
Reynolds & Kamphaus, 2006) uses teacher report to measure school 
performance/problems at baseline and posttreatment. The BASC-2 teacher report 
includes 100 items that are rated on a 4-point scale of frequency of occurrence. There are 
numerous composites and subscales on the BASC-2, but the subscales of interest for the 
current study were School Problems, Learning Problems, and Study Skills. For the 
clinical scales (School Problems, Learning Problems), T-scores of below 60 are 
considered normal, while scores from 60-69 are at-risk, and scores above 70 are clinically 
significant. For the adaptive scales (Study Skills), T-scores of 41-59 are average, 31-40 
are at-risk, and scores 30 and below are considered clinically significant. Internal 
consistency of composite scores has been shown to be adequate (.90), while subscale 
scores across teacher, parent, and student forms have internal consistencies of .80. Test-
retest reliability of composites on the BASC-2 is .80, while subscale reliability ranges 
between .70 to .80 (Reynolds & Kamphaus, 2006). The BASC-2 was completed by the 
teachers of 2 participants with BD.  
Eleven subjects with BD and 3 comparison participants were on summer break 
from school during participation in the study and were unable to have academic 
performance rated by teachers. Additionally, 3 participants with BD and 3 comparison 
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participants were not students during the study because they had completed or 
discontinued an academic program and therefore, did not complete academic 
performance ratings. Two participants chose not to have teachers rate their academic 
performance. Two participants with BD and 1 comparison participant did not return the 
academic measures. There were 2 participants with BD and 3 comparison participants 
that completed measures of academic performance at the baseline and final study visits. 
These participants were both in the uridine group. Academic performance measures were 
intended to evaluate academic performance and functioning for all participants in the 
study. Since these measures were only completed by 2 participants in the same BD group, 
they were not used in the final analyses. Each of the 2 participant’s teachers completed 
two measures that provided information about the participant’s academic performance 
and functioning.  
 
Interrater Reliability 
The principal investigator was trained on all mood, neuropsychological, and 
academic measures.  For reliability purposes, the principal investigator and Dr. Kondo 
completed all diagnostic interviews and mood rating scales. Thirty-three percent of 
interviews and mood rating scales were randomly selected and rated by both Dr. Kondo 
and the principal investigator. Interrater reliability was calculated to determine 
consistency among raters for the K-SADS/SCID, CDRS-R, MADRS, and YMRS using 
Cohen’s kappa. According to kappa ratings by Landis and Koch (1977), each measure 
was found to have substantial (K = .61 to .80) or almost perfect agreement (K = .81 to 
.99). The interrater reliability for diagnostic interviews was found to have almost perfect 
agreement, K = .93, p < .001. Depression ratings were found to have substantial 
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agreement CDRS-R, K = .751, p < .001, and MADRS, K = .73, p < .001. Additionally, 
interrater agreement on the YMRS was found to have substantial agreement, K = .66, p < 
.001. Only the principal investigator administered and scored the neuropsychological 
tasks and the academic performance checklists.  
 
Treatment Integrity 
Participants’ adherence to treatment was measured throughout the study. At each 
weekly study visit, participants were given a supply of placebo-controlled uridine. 
Participants were given a weekly log to write the time of day (morning and night) that 
they took the placebo-controlled uridine and had a parent initial at that time. If 
participants did not live with a parent, they initialed for themselves. Participants brought 
their logs to each weekly study visit and discussed any missed doses. If participants did 
not remember to bring logs or study medication to a weekly visit, they were asked to 
bring it to the next consecutive visit. Logs were discussed at each visit and leftover study 
medication was counted at each visit. Any missed study medication doses and the amount 
of study medication returned at each visit were noted on a master log for each participant. 
Two participants did not return logs or left over study medication throughout the study, 
but their parent confirmed that study medication was taken each day and that no doses of 
study medication were missed.  
Treatment adherence was calculated for each participant, and it was found that 3 
participants missed more than the 10% established cut-off amount of placebo-controlled 
uridine doses throughout the study. These participants were considered non-adherent and 
were not included in the data analyses. All missed doses were discussed with participants 
and their parents. Participants were asked to set a reminder to take all study medication. 
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One participant taking the placebo missed one dose of study medication during the 2nd 
and 5th weeks of the study. During the 3rd and 4th week of the study, the participant did 
not miss any doses of study medication. The final week of the study, the participant 
brought back all but one day of study medication for that week, which indicated that 
participant missed 6 doses of study medication that week. The participant missed a total 
of 8 doses of study medication throughout the study.  
One participant taking uridine did not bring back their log or any left over study 
medication throughout the study. At the week 6 visit, the participant brought back 48 
capsules of study medication and had missed 7 days of study medication. Another 
participant taking uridine reported missing approximately 1 dose of uridine each week. 
This participant was asked to set an electronic reminder to take the study medication. 
Additionally, this participant brought back all left over study medication at week 6 and 
stated that they had missed 2 doses that week.  Over the course of the study, the 
participant had missed a total of 10 days of study medication. 
During the study, 2 participants missed one weekly study visit. One of the 
participants started a new job and forgot to attend the week 4 visit, despite reminder 
text/phone calls. The other participant went on a camping trip to a remote location 
without cell phone service, and even though a phone visit was offered that week, the 
week 3 visit was not possible.  All participants were able to attend appointments either in 
person or by phone when an in-person visit was not possible. There were not any 
participants who missed 2 consecutive weekly study visits during the study or were 
removed from the study due to noncompliance. Therefore, all but 3 of the 30 total 





The current study utilized 2 x 2 mixed factorial designs that used both between-
group and repeated measures to compare mean differences of composites for BD 
participants who received uridine to those who received placebo pre- and posttreatment.  
The between-group variable was the treatment that participants with BD were 
randomized and administered (uridine vs. placebo).  The repeated measures variables 
were the measurement of mood symptoms and neuropsychological performance over 
time (pretreatment vs. posttreatment). The larger study from which the data for this study 
were drawn represented a repeated measures design. In that study, mood was measured 
weekly for participants with BD who had been administered placebo-controlled uridine. 
To answer the third research question, data were graphed utilizing scatter plots and tested 
for a quadratic effect of time on mood symptoms for the participants with BD taking 
uridine.  
The first supplemental research question utilized between-subjects analysis of 
variance (ANOVA) to compare baseline neuropsychological performance of participants 
with BD to unaffected comparison participants. Academic and educational histories of 
bipolar and unaffected comparison participants were summarized and Fisher’s exact test 
of independence was used to analyze educational experiences of both groups in the 
second supplemental question. Since participants were on break from school, and some 
participants did not attend school, questionnaires were not completed by a teacher. The 
third supplemental question utilized bivariate correlations to examine each academic 






Descriptive statistics were calculated for all demographic and clinical variables 
using means and standard deviations for each sample. Participant performance on 
individual measures was described by calculating the total raw score for each variable 
and standardizing (i.e., converting to z-scores) both baseline and posttreatment scores 
relative to performance of the unaffected comparison participants’ performance on each 
assessment variable at baseline. Expressing all scores in the same units facilitated 
comparisons of variables across occasions, and the combination of similar variables to 
form composites.  
 All variables were checked for normality, including skew, kurtosis, and 
homogeneity of variance. Outliers were defined as scores that were greater than 3 z-
scores. In cases where outliers were detected, the individual data point was examined first 
to verify that it did not result from a data error and represented a valid case. For outliers 
deemed to be valid, the data point was retained, but the score was converted to +/- 3.0 to 
decrease its influence (Tabachnick & Fidell, 2007).  
Since there were a smaller number of subjects than expected, it was not possible 
to use factor analysis to form composites. Using standardized scores, composites were 
formed for each of the domains based on theory from previous studies, and correlation 
between the variables as evidenced by a correlation matrix. All variables combined into 
composites had correlations > .4.  
Composites were formed by adding or subtracting the standardized variables and 
dividing by the total number of variables combined together for the following domains: 
depression, attention, memory, verbal memory, executive functioning, and processing 
speed. Using the five neuropsychological composites, a global neuropsychological 
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composite score was created by averaging the five composites together.  Correlations of 
baseline composites are displayed in Table 4.  
The depression composite was comprised of the total score for the Children’s  
Depression Rating Scale (CDRS) and the total score for the Montgomery-Asberg  
Depression Rating Scale (MADRS). The neuropsychological domain composites were 
constructed as follows: Attention composite based on the Conners Continuous 
Performance Test-Third Edition (CPT-3); Executive Function composite based on the 
Wisconsin Card Sorting Test (WCST), Delis-Kaplan Executive Function System D-KEFS 
Trails, and Color Word Interference Test; Working Memory composite based on the 
Wechsler Adult Intelligence Scale-4th Edition (WAIS-IV) Working Memory Index; Verbal 
Memory composite based on scores from the California Verbal Learning Test-Second  
 
Table 4. Correlation Matrix for Baseline Composites. 
_______________________________________________________________________ 
          Executive     Verbal     Processing 
 Composite      Depression  Attention   Memory    Function_    Memory_ __Speed _   
 
Depression              -- 
 
Attention              -.121        --              
 
Memory               -.392   .502*             --               
 
Executive            -.378   .641**        .648**            --  
Function            
 
Verbal                 -.284       .374           .460*      .481*         --       
Memory       
 
Processing           -.214            .493*        .777**      .671*   .334            --  
Speed  
________________________________________________________________________ 
**p < .01, **p < .05  
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Edition (CVLT-II); and Processing Speed composite based on the Wechsler Adult 
Intelligence Scale-4th Edition (WAIS-IV) Processing Speed Index. See Table 5 for the 
domains, measures, and the variables that were included in each composite.  
Research questions were addressed through 2 x 2 mixed factorial designs which 
used both between-group and repeated measures to compare mean differences of 
composites for BD participants who received uridine to those who received placebo pre- 
and posttreatment. The third research question utilized scatter plots and tested for a 
quadratic effect of time on mood symptoms for the participants with BD taking uridine.  
Between-participant analysis of variance (ANOVA) was used for the first 
supplemental research question to compare baseline neuropsychological performance of 
participants with BD to unaffected comparison participants. The second supplemental 
question summarized and compared academic and educational histories of bipolar and 
unaffected comparison participants using Fisher’s exact test of independence. The third  
supplemental question used bivariate correlation analyses to examine the relationship  
between performance on neuropsychological composites and academic experiences.   
All analyses were conducted using SPSS. Bonferroni correction was used due to 
multiple comparisons, statistical significance of p < .05/6 = .0083 was used for research 









Table 5. Measures and Scoring by Domain Composite 
______________________________________________________________________ 
    Domain               Measure                         Scores used for composite     
 
Depression             Children’s Depression Rating Scale      total raw score 
                               Montgomery-Asberg Depression           total raw score 
                   Rating Scale 
 
Attention                Conners Continuous Performance        detectability 
                               Test- II                                     omission errors 
               commission errors 
               variability  
 
Executive               Wisconsin Card Sorting Test                 perseverative response   
  Function                                                nonperseverative errors  
                               D-KEFS Trail Making Test           time to complete (in sec) 
               total errors 
                               Color Word Interference Test                inhibition self-corrected errors 
               inhibition total time 
               inhibition switching sc errors 
               inhibition switching time 
 
Working                Wechsler Intelligence Scale-IV               digit span total raw score 
Memory               Working Memory Index                        letter-number sequencing 
                total raw score  
        
Verbal                    California Verbal Learning Test-II        trial 5  
  Memory                short delayed free recall 
                 long delay free recall 
                recognition            
       
Processing             Wechsler Intelligence Scale-IV               coding total raw score 












There were a total of 30 participants in the study. There were 20 participants in 
the Bipolar Disorder (BD) group, and their ages ranged from 14 to 21 years old.  The 
mean age of participants in the BD group was 17.6 years old, with a standard deviation of 
2.5 years. The ages of participants were similar between the bipolar and comparison 
groups, with participants in the unaffected comparison (UC) group ranging age from 16 
to 21 years and the mean age being 19.0 years with a standard deviation of 1.56. Sixteen 
participants with BD identified their race as Caucasian, 2 as Native Hawaiian, 1 as 
Persian, and 1 as multiracial. Two participants with BD identified their ethnicity as 
Hispanic/Latino. In the unaffected comparison group, 1 participant identified his or her 
race as multiracial, and 2 participants identified their ethnicity as Hispanic/Latino. There 
were more female (65%) participants than males (35%) in the BD sample. Table 6 shows 
the combined means of the bipolar groups on participant characteristics and separate 
means of the placebo, uridine, and comparison groups, which are similar across most 
participant characteristics.  It is important to note that only 17 participants with BD were 
included in the final analyses due to 3 being removed for nonadherence. Eighteen 





Table 6. Participant Characteristics (N = 30). 
 
    Bipolar Participants        Uridine Group           Placebo Group               Comparison Group 
              (N = 20)       (N = 11)                (N = 9)                                 (N = 10)  
 
Mean Age (SD)   17.60 (2.50)               16.91 (2.39)               18.44 (2.51)                       19.0 (1.56) 
Number of Females (% of sample      13 (65%)                8 (73%)                  5 (56%)                5 (50%)                                             
Number of Males (% of sample)  7 (35%)                3 (27%)                  4 (44%)     5 (50%) 
Psychotropic Meds (% of sample)      14 (70%)                        8 (73%)                         6 (67%)                                 0 (0%) 
No Medication (% of sample)              6 (30%)                3 (27%)                          3 (33%)                   0 (0%) 
ADHD Diagnosis (% of sample)         6 (30%)                         3 (27%)                          3 (33%)                                 0 (0%) 
Prior Psych Hospitalization                  8 (40%)     4 (36%)        4 (44%)       0 (0%)  




were diagnosed with Bipolar NOS. Secondary diagnoses included Panic Disorder, 
Generalized Anxiety Disorder, Social Phobia, Post-Traumatic Stress Disorder, Obsessive 
Compulsive Disorder, Separation Anxiety Disorder, Specific Phobia, Attention Deficit 
Hyperactivity Disorder, and Autism Spectrum Disorder. Table 7 lists current and past 
secondary diagnoses for participants with BD. All participants in the unaffected 
comparison group did not meet criteria for a DSM-IV diagnosis. 
Fourteen participants with BD were taking psychotropic medications during the 
study and 6 participants were not taking any medications. Participant medications are 
 
Table 7. Secondary Diagnoses for Bipolar Participants 
 
         DSM-IV Diagnosis         # Participants              % of sample    
Current Secondary Diagnoses 
   Panic Disorder            7            35%             
   Generalized Anxiety Disorder         3        15%              
   Social Phobia                5        25%       
   Post Traumatic Stress Disorder               6       30%   
   Obsessive Compulsive Disorder             6       30%   
   Separation Anxiety Disorder              3                                  15%       
   Specific Phobia           3       15%  
   ADD/ADHD           6       30%       
   Autism Spectrum Disorder                     3       15%  
  
Past Secondary Diagnoses 
    
  Anorexia Nervosa            1                                    5%           
   Bulimia Nervosa           1                                    5%  
   Alcohol Abuse                        6                                  30%       
   Alcohol Dependence                             4                                  20%   
   Cannabis Abuse                              3                                  15%   
   Cannabis Dependence                       3                                  15%      
   Cocaine Abuse                   1                                    5%  
   Poly Drug Abuse                   2                                  10%       
   Poly Drug Dependence                      1                                    5%   




listed in Table 8 and included mood stabilizers (lithium, lamotrigine, divalproex); 
antidepressants (duloxetine, sertraline, citalopram, bupropion, fluoxetine); antipsychotics 
(ziprasidone, risperidone, quetiapine); medications for anxiety (hydroxyzine, buspirone, 
alprazolam, clonazepam); and medications for attention problems (Strattera, Concerta).  
Participants were given the WASI-II as an abbreviated measure of IQ. Both 
groups of participants with BD had similar cognitive scores as the unaffected comparison 
group. On the two-subtest WASI-II, standard scores of participants with BD ranged from  
 
Table 8. Psychotropic Medications for Bipolar Participants. 
 
     Medication                                 BD Participants      Placebo          Uridine     
Mood Stabilizer       9 (45%)  5                     4        
   Lithium        2 (10%)           2                     0  
   Lamotrigine       6 (30%)             3            3 
   Divalproex            1 (5%)      0            1 
 
Antipsychotic       3 (15%)     2            1  
   Ziprasidone       1 (5%)      1                     0 
   Risperidone          1 (5%)  1                     0 
   Quetiapine       1 (5%)      0                    1  
 
Antidepressant     11 (50%)             4            7  
   Duloxetine      1 (5%)     0                     1 
   Sertraline      2 (10%)     1                     1 
   Citalopram      2 (10%)         0                     2 
   Bupropion      4 (20%)     2                     2  
   Fluoxetine                       2 (10%)       1                     1 
 
Anxiety Medication      5 (25%)   2            3  
   Hydroxyzine                                      2 (10%)                0            2         
   Buspirone      1 (5%)    1            0 
   Alprazolam      1 (5%)      0                     1 
   Clonazepam      1 (5%)      1            0 
 
ADHD Medication     3 (15%)     1            2 
   Strattera      1 (5%)           1            0 





86 to 136 with a mean of 108.3 and a standard deviation of 13.59. Standard scores of 
participants in the comparison group on the two-subtest WASI-II ranged from 96 to 118 
with a mean of 105.8 and a standard deviation of 8.53.   
 
Results of Research Question 1 
Are there significant differences in depressive symptoms after 6 weeks of placebo-
controlled uridine administration between adolescents with BD taking uridine (N=11) 
and those taking a placebo (N=9)? 
To address differences between depressive symptoms after 6 weeks of placebo-
controlled uridine administration for adolescents with BD taking uridine and those taking 
the placebo, the depression composite was analyzed using a 2 x 2 mixed factorial design. 
The pre- and posttreatment measures of the depression composite were used as the 
repeated-measures factor and the treatment variable (uridine vs. placebo) was used as the 
between-subjects factor. 
Due to Bonferroni correction, all effects are reported significant at p < .0083. 
There was a significant main effect for change in depressive symptoms from pre- to 
posttreatment, F(1, 15) = 29.56, p < .001, partial η2 = .66. There was no significant main 
effect for treatment between the uridine and placebo groups, F(1, 15) < 1. Furthermore, 
the results showed that there was not a significant interaction effect between the 
treatment and depression ratings from pre- to posttreatment, F(1, 15) = 6.08, p > .01. This 
indicates that depressive symptoms decreased from baseline to the final visit for 
participants with BD; however, there was not a significant difference in the report of 
depressive symptoms between BD participants taking uridine and those taking the 
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depressive symptoms between BD participants taking uridine and those taking the 
placebo from pre- to posttreatment. Figure 4 displays the change in the depression 
composite for the placebo and uridine groups from pre- to posttreatment.  
Treatment response in bipolar disorder research has been defined as a reduction of 
50% in depressive symptoms on the CDRS-R or MADRS (Patel et al., 2006). Seven of 
the 17 participants (41% of BD sample) showed a treatment response; however, only 3 of 
those participants were administered uridine. Table 9 displays the means and standard 
deviations for the uridine and placebo groups on the CDRS-R and MADRS at baseline 
and posttreatment.  






















Uridine	  Group	  Placebo	  Group	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Table 9. Means and Standard Deviations on Depression Measures   
__________________________________________________________ 
Depression Measure           Placebo Baseline _       Uridine Baseline  _                   
  
CDRS-R             63.75 (5.44)                58.11 (5.23)                     
 
MADRS             34.50 (4.75)                28.67 (6.32)  
__________________________________________________________ 
Depression Measure __      Placebo Final ___          Uridine Final__ _   
 
CDRS-R             37.75 (14.44)                  46.89 (14.79)           
 
MADRS              14.25 (10.71)                  22.67 (12.04)               
_______________________________________________________________________________________ 
CDRS = Children’s Depression Rating Scale-Revised 
MADRS = Montgomery-Asberg Depression Rating Scale  
 
Results of Research Question 2 
Are there significant differences in performance on neuropsychological tasks 
(e.g., memory, attention, etc.) after 6 weeks of placebo-controlled uridine administration 
between adolescents with BD taking uridine (N = 11) and those taking placebo (N=9)?  
To address the differences between performance on neuropsychological tasks 
after 6 weeks of placebo-controlled uridine administration for adolescents with BD taking 
uridine and those taking the placebo, each neuropsychological composite was analyzed 
using a 2 x 2 mixed factorial design. The pre- and posttreatment measures for each 
neuropsychological composite were used as the repeated-measures factors and the 
treatment variable was used as the between-subjects factor. 
 
Attention 
The CPT-II was administered to both groups to assess attention pretreatment and 
following 6 weeks of placebo-controlled uridine administration. A 2 x 2 mixed factorial 
design was used to compare mean attention composite scores to determine if there were 
!!
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any differences between the uridine and placebo groups from pre- to posttreatment. 
Results revealed that there was a significant main effect for change in attention from pre- 
to posttreatment, F(1, 15) = 12.74, p < .01, partial η2 = .46.  There was no significant 
main effect for treatment between the uridine and placebo groups, F(1, 15) = 1.64, p > 
.05. The results showed that there was no significant interaction effect between the 
treatment and attention performance from pre- to posttreatment, F(1, 15) < 1. Both the 
uridine and placebo groups improved in performance in attention on the CPT-II from 
baseline to posttreatment; however, there were no significant differences between the 
groups. Figure 5 displays the changes in the attention composite for the placebo and 
uridine groups from pre- to posttreatment. Additionally, Table 10 displays the z-scores of 
neuropsychological composites based on performance by participants in the uridine and 
placebo groups at the baseline and following 6 weeks in the study.  
 
 

























Table 10. Z-Scores and Standard Deviations on Neuropsychological Domains for Participants With BD 
___________________________________________________________________________________________________________ 
Neuropsychological           Placebo                              Uridine                        Placebo                     Uridine 
Domain                                                     Baseline                     Baseline                         Final                         Final                     
___________________________________________________________________________________________________________                                   
 
Attention       -.5851 (1.25)                    -.9192 (0.82)                  -.0722 (0.98)          -.3618 (0.85) 
 
Executive Function                 -.4543 (0.77)            -.4682 (0.86)   .0855 (0.68)           .4000 (0.69) 
 
Working Memory                                -.2665 (1.26)                      -.3878 (1.13)  -.2325 (0.89)         -.3369 (1.18) 
 
Verbal Memory         -.6610 (0.79)           -.3785 (1.39)  -.3968 (1.27)         -.0318 (1.49)  
          























Performance in executive functioning was examined using subscales from the 
TMT, CWIT, and the WCST. These measures were administered to BD participants at 
baseline and posttreatment treatment to examine executive functioning performance. 
Table 10 displays z-scores of the executive functioning composite for both treatment 
groups at baseline and the final visit. A 2 x 2 mixed factorial design was used to compare 
mean executive functioning composite scores to determine if there were any differences 
between the uridine and placebo groups from pre- to posttreatment.  
Results revealed that the main effect for change in performance on executive 
functioning from pre- to posttreatment was significant, F(1, 15) = 16.19, p < .01, partial 
η2 = .52. This indicates that participants with BD improved their performance on 
executive functioning tasks from pre- to posttreatment. There was no significant main 
effect for treatment between uridine and placebo groups, F(1, 15) < 1.  The interaction 
between treatment and executive functioning performance from pre- to posttreatment was 
also not significant. This suggests that overall the bipolar group improved performance in 
executive functioning from baseline to posttreatment, but there was not a significant 
difference in executive functioning performance between the uridine and the placebo 
groups from pre- to posttreatment. Figure 6 displays the executive functioning composite 
for the placebo and uridine groups from pre- to posttreatment. 
 
Working Memory 
Participants were administered the Working Memory composite of the WAIS-IV 
to assess working memory. A mixed 2 x 2 factorial design was used to compare mean 
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Figure 6. Mean Executive Functioning Composite Z-Scores Pre- and Posttreatment 
working memory composite scores to determine if there were any differences between 
the uridine and placebo groups from pre- to posttreatment. Results revealed that there was 
not a significant main effect for change in working memory, F(1, 15) < 1. Working 
memory performance proved to be consistent for participants with BD. There was not a 
significant main effect for treatment between uridine and placebo groups, F(1, 15) < 1. 
Also, there was not a significant interaction effect between the treatment and working 
memory performance from pre- to posttreatment, F(1, 15) < 1.  The working memory 
composite for the placebo and uridine groups from pre- to posttreatment is illustrated in 
Figure 7. Memory scores for participants in the placebo and uridine groups were similar 
and there was not a significant difference in performance between the groups from 




































Figure 7. Mean Working Memory Composite Z-Scores Pre- and Posttreatment 
 
Verbal Memory 
Participants with BD were administered the CVLT-II pre- and posttreatment to 
assess verbal memory. A mixed 2 x 2 factorial design was used to compare mean verbal  
memory composite scores to determine if there were any differences between the uridine 
and placebo groups from pre- to posttreatment. The main effect of change in verbal 
memory from pre- to posttreatment was not significant, F(1, 15) < 1.  Participants with 
BD scored similarly on the CVLT-II over time. There was no significant main effect for 
treatment between uridine and placebo groups, F(1, 15) = 2.37, p > .05.  Further, the 
results failed to show a significant interaction between the BD treatment groups and 
verbal memory performance from pre- to posttreatment, F(1, 15) = 1.13, p > .05.  As 
displayed in Figure 8, both participants taking uridine and participants taking placebo 
showed little change in performance on verbal memory, and there was not a significant 



































Figure 8. Mean Verbal Memory Composite Z-Scores Pre- and Posttreatment  
 
Processing Speed 
Measures from the WAIS-IV, including the Coding and Symbol Search subtests, 
were administered to participants with BD pre- and treatment to assess processing speed. 
Table 10 displays z-scores for the processing speed composite for both groups at 
baseline and after 6 weeks of treatment. A mixed 2 x 2 factorial design was used to 
compare mean processing speed composite scores to determine if there were any 
differences between the uridine and placebo groups over time. Figure 9 displays the 
executive functioning composite for the placebo and uridine groups from pre- to 
posttreatment. 
There was no significant main effect for change in processing speed from pre- to 
posttreatment, F(1, 15) = 8.49, p > .05.  Participants with BD performed similarly on 



































Figure 9 Mean Processing Speed Composite Z-Scores Pre- and Posttreatment 
 
main effect for treatment between uridine and placebo groups, F(1, 15) = 1.64, p > .05. 
Additionally, the results showed that there was not a significant interaction effect  
between the treatment and processing speed performance from pre- to posttreatment, F(1, 
15) < 1.  This indicates that there was not a significant difference in processing speed 
performance between BD participants taking uridine and those taking the placebo from 
pre- to posttreatment.  
 
Results of Research Question 3 
For adolescents with BD taking uridine, is there a quadratic effect of time on 
depressive symptoms?   























depressive ratings were analyzed for BD participants taking uridine. Scatter plots were 
utilized to visually analyze depression ratings for participants throughout the study. 
Depression ratings from each week of the larger placebo-controlled uridine study 
were plotted to evaluate the change in depression scores. Figure 10 displays the uridine 
and placebo groups mean CDRS-R depression ratings change over the course of the 
larger study. This graph revealed that the biggest change in mean depression scores for 
the uridine and placebo groups occurred during the 1st week of the study. There was 
approximately a 10-point decrease in mean CDRS-R scores from the baseline visit to the 
week 1 visit for both the uridine and placebo groups. Following the 1st week study, the 
uridine group leveled off and the placebo group continued to slowly improve.  
 
 




























Further analysis of all CDRS-R scores and MADRS scores for participants in the  
uridine group throughout the placebo-controlled uridine study utilizing scatter plots 
revealed that 3 participants had a greater decrease in depression ratings than the rest of 
the group. In fact, these were the 3 participants that had a treatment response to uridine. 
For the 3 participants that had a treatment response, the greatest decrease in scores 
happened during the 1st week that participants were taking uridine. Following that week, 
there was a small steady decrease in depression scores that ranged 5 to 10 points. For the 
other participants in the uridine group, there was minimal change over time in depression 
scores. Furthermore, there did not appear to be a quadratic effect of time of uridine on 
depressive symptoms for participants in the uridine group.  
 
Results of Supplemental Research Question 1 
What are the differences in prestudy performance on neuropsychological tasks 
between comparison subjects (NB=10) and depressed adolescents with BD (N=20)?   
To address the differences between performance on neuropsychological tasks 
between nonaffected comparison subjects and adolescents with BD, each 
neuropsychological composite was analyzed using between-subjects analysis of variance 
(ANOVA). The baseline treatment measures for each neuropsychological composite were 
used as dependent variables and the group (bipolar disorder vs. unaffected) was the 
between-subjects factor. Due to multiple neuropsychological comparisons, Bonferroni 
correction was used and all effects are reported with a statistical significance level of p < 






 Between-subjects ANOVA compared mean attention composite scores from 
baseline for participants with BD and unaffected comparison participants to determine if 
there were any differences between groups. Results of the ANOVA demonstrated that 
attention performance differed between the two groups, F(1, 28) = 6.58, p < . 05. 
However, these differences were not considered to be statistically significant (p =.016).  
On the CPT-3, participants with BD made more errors of commission and omission than 
unaffected comparison participants. Additionally, participants with BD had more 
difficulty distinguishing the target from nontargets (detectability) and were more variable 
(less consistent) when responding; however, these differences were not statistically 
significant. Figure 11 illustrates the mean difference between groups. Table 11 displays 
the means and standard deviations of measures that contribute to neurocognitive 
composites based on performance by participants in the BD and comparison groups.  
 
Executive Functioning 
Between-groups ANOVA was used to determine if the participants with BD and 
comparison participants differed on executive performance. Results showed that 
executive functioning performance differed significantly between the two groups, F(1, 
28) = 4.23, p < . 05, but not at the p < 01. Figure 11 displays that participants with BD 
performed worse than comparison participants on tasks that involved response inhibition 






















* p < 0.05






Table 11. Z-scores and Standard Deviations on Neuropsychological Domains for All Participants 
___________________________________________________________________________________________________________ 
Neuropsychological     Bipolar Group                   Comparison           Bipolar Group          Comparison 
Domain                                                     Baseline               Group Baseline                   Final                   Group Final                     
___________________________________________________________________________________________________________                                   
 
Attention       -.7620 (1.03)                     .0000 (0.88)                 -.2255 (0.90)           -.1661 (1.27) 
 
Executive Function                 -.4617 (0.80)             .0000 (0.67)   .2520 (0.69)           -.0861 (0.81) 
 
Working Memory                                -.3308 (1.16)                       .0000 (0.94)  -.2878 (1.02)            .0947 (1.18) 
 
Verbal Memory                 -.3271 (1.30)            .0000 (0.81)  -.3111 (1.40)            .0567 (1.49)  
          
Processing Speed                    -.3508 (1.50)             .0000 (0.94)  -.2007 (1.45)            .3995 (1.21)  






 Between-subjects ANOVA that compared mean working memory between 
participants with BD and unaffected comparison participants did not demonstrate a main 
effect between groups, F(1, 28) = 1.87, p > . 05. This means that there were no significant 
differences in performance on working memory tasks at baseline between participants 
with bipolar disorder and unaffected comparison participants. 
 
Verbal Memory 
 Similarly, between-subjects ANOVA that compared mean verbal memory at 
baseline between participants with BD and unaffected comparison participants did not 
demonstrate a main effect between groups, F(1, 28) = 2.92, p > .05. This suggests that 
performance on verbal memory items from the CVLT-II was similar between participants 
with bipolar disorder and unaffected comparison participants.  
 
Processing Speed 
Between-subjects ANOVA compared mean processing speed composite scores 
from baseline for participants with BD and unaffected comparison participants to 
determine if there were any differences between groups. Results of the ANOVA revealed 
that processing speed performance differed between the two groups, F(1, 28) = 3.48, p < 
.05, but was not statistically significant. Figure 11 demonstrates that comparison 
participants outperformed participants with bipolar disorder on processing speed tasks. 
Although not quite statistically significant, these findings are important. These outcomes 
are not unexpected and longitudinal studies have shown that processing speed deficits are 
associated with functional outcomes for individuals with BD (Burdick et al., 2010).  
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Results of Supplemental Research Question 2 
What are the differences in prior educational experiences between unaffected 
comparison participants and adolescents with BD? 
Fisher’s exact test of independence was used to examine the differences in 
educational experiences between participants with BD and unaffected comparison 
participants. Each categorical educational variable (see Appendix B for Academic and 
Educational History Report Form) was analyzed between the bipolar and comparison 
group using Fisher’s exact test. As shown in Table 12, the mean number of years of 
education for unaffected comparison participants was 12 years with a standard deviation 
of 1.49 years, while participants with BD had a mean of 11.05 years of education and a 
standard deviation of 2.33 years. Despite a similar number of years of education, the 
educational experience reported by many of the bipolar participants was relatively 
different than unaffected comparison participants. Analyses of participant self-reports 
using Fisher’s exact test indicted that participants with BD were more likely to report 
academic difficulties than unaffected comparison participants (p =.002). 
According to participant report regarding educational experiences, many 
participants with BD reported absences from school and the inability to complete 
assignments/homework during extreme mood episodes. Bipolar participants reported that 
during a mood episode they had fallen behind in coursework, which resulted in feeling 
overwhelmed and unable to make up work before the grading term was over. Applying 
Fisher’s exact test, participants with BD were more likely to report discontinuing 
education (p = .029) than unaffected comparison participants. Eight of the 
participants with bipolar disorder (40%) reported discontinuing a program, school, or  
college due to difficulties associated with a mood episode, primarily depression. Six 
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Table 12. Participant Educational Characteristics.  
 
BD Participants          Comparison Participants 
______________________________         N = 20         N = 10________ 
         
Years of Education (SD)                         11.05 (2.33)              12.00 (1.49) 
Academic Difficulties           12 (60%)                              0 (0%)           
Discontinued Education                              8 (40%)        0 (0%) 
Break from School                                      6 (30%)                               1 (10%) 
Transferred Programs/Schools                    9 (45%)                               0 (0%) 
Alternative School/Program                        5 (20%)                   0 (0%) 
Had IEP or 504 Plan                        5 (25%)                   0 (0%) 
________________________________________________________________________ 
 
participants with BD stated that they experienced a severe mood episode that resulted in a 
break from school, which was associated with hospitalization for 4 participants. One 
unaffected comparison participant was taking a semester break from college due to 
financial reasons. No statistically significant differences were observed with Fisher’s 
exact test between bipolar or comparison participants with regard to taking a break from 
school (p = .37). 
According to Fisher’s exact test, participants with BD were more likely to transfer 
to new programs or schools than comparison participants (p = .013).  Nine participants 
transferred to different schools, programs, or colleges when they experienced difficulty 
during a bipolar episode. Five participants reported attending alternative schools or 
programs; 2 of the students elected to complete courses exclusively online. The 2 
participants who completed online courses reported that this was a flexible alternative to 
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live courses and that courses online helped them manage anxiety. Additionally, two 
participants transferred out of International Baccalaureate (IB) and honors courses to 
mainstream courses so that the workload was more manageable. Using Fisher’s exact 
test, no statistically significant differences were observed between bipolar or comparison 
participants in attending alternative programs/schools (p = .14). 
Four participants with bipolar disorder stated that they had an Individualized 
Education Program (IEP) and received special education services at school. Of these, 3 
participants had IEPs for emotional and behavioral disorders and 1 participant had an IEP 
for math. One participant reported that she had a 504 plan and received accommodations 
at school for her diagnoses of BD and ADD. However, no statistically significant 
differences were found between bipolar or comparison participants in the study receiving 
special education services using Fisher’s exact test (p = .14). 
 
Results of Supplemental Research Question 3 
Is there a relationship between performance on neuropsychological tasks and 
academic difficulties for participants with BD? 
To investigate the relationship between performance on neuropsychological tasks 
and reports of academic difficulties, each baseline neuropsychological composite was 
correlated with participants’ report of having academic difficulties. This was done using 
bivariate correlations. As seen in Table 13, there was a significant relationship between 
participants who received special education services and their performance on tests of 
attention, r = -.375, p < .05, working memory, r = -.539, p < .01, executive functioning, 






Correlation Matrix for Academic Difficulties and Composites 
____________________________________________________________________________________________________ 
                Working        Executive           Verbal          Processing 
                                     Depression     Attention          Memory           Function            Memory           Speed        _   
 
Special Education                  -.376       -.375*               -.539**           -.611**             -.330             -.572** 
 
Academic Difficulties       .085       -.394*               -.381*           -.315                -.054  -.459* 
 
Alternative Education      -.054        -.228                 -.307           -.274                 .112   -.442* 
  
Discontinued Education         .179        -.198                 -.001           -.160                 .122   -.303 
  
Transferred Education          .139        -.199                 -.112           -.151                 .005   -.365* 
 
Break from Education                  .392        -.000                -.040             .062                 .086    .017 
 
ADHD Diagnosis           -.281        -.135                -.367*            -.225                -.231   -.184 
           
Psychiatric                              .186        -.181                -.074            -.071                 .042   -.154      
Hospitalization       
 
WASI-II Score       .206         .394*                .485**            .604**                .203   .516** 
 
____________________________________________________________________________________________________ 
**p < .01, *p < .05  
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services was associated with lower performance on attention, working memory, executive 
function, and processing speed tasks. Additionally, there was a significant relationship 
between reported academic difficulties and attention, r = -.394, p < .05, working memory, 
r = -.381, p < .05, and processing speed, r = -.375, p < .05.  Participants who self-reported 
experiencing academic difficulties had more attention, working memory, and processing 
speed deficits. 
There was a significant relationship between participants enrolled in alternative 
education programs or schools and processing speed task performance, r = -.442, p < .05. 
Enrollment in alternative classes, programs, or schools was associated with lower 
processing speed scores. Additionally, participants who had transferred to new classes, 
programs, or schools had a significant relationship with processing speed test 
performance, r = -.365, p < .05.  Lower processing speed performance was associated 
with transferring to different classes, programs, and schools. A significant correlation was 
found for participants with an ADHD diagnosis in terms of working memory test score (p 
< .05); surprisingly, it was not significantly correlated with lower scores on attention or 
processing speed. 
Furthermore, the total score on the WASI-II, an abbreviated test of intelligence 
comprised of Vocabulary and Matrix Reasoning, was significantly correlated with 
attention (p < .05), working memory (p < .01), executive functioning (p < .01), and 
processing speed (p < .01).  Higher scores on the WASI-II were correlated with higher 







 Currently, there are no treatments designed specifically for use with adolescent 
bipolar depression. Many psychotropic medications that are used to treat bipolar 
depression may further exacerbate pre-existing neurocognitive deficits experienced by 
these youth. This study was an attempt to study the efficacy of uridine as a novel 
treatment for depression. Uridine is among similar pyrimidines that have shown success 
in reducing depressive symptoms in previous studies of BD adults and adolescents. 
Pyrimidines, including uridine, have shown neurocognitive benefits such as increased 
attention and working memory performance in healthy participants. Thus, this study set 
out to evaluate the effects of uridine on depressive symptoms and the potential 
enhancement of cognitive functioning.  
 Furthermore, the current study intended to replicate previous findings of 
neuropsychological deficits in youth with bipolar disorder in a depressed episode. This 
study also examined the association between neuropsychological performance and 
educational experience for youth with BD.
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Major Research Findings 
Treating Bipolar Depression With Uridine  
        In the efficacy analysis, both groups of BD participants showed significant 
improvements in the depressive symptoms from baseline to week 6, although participants 
treated with uridine did not differ significantly from those administered a placebo with 
regard to decreasing symptoms of depression. Thirty-three percent of participants with 
BD who were administered uridine showed a treatment response. This can be compared 
to treatment response rates of 50 to 56% in randomized, double-blind, placebo-controlled 
trials of pharmacotherapies used as treatment for bipolar depression (Iovieno, Walker, & 
Papakostas, 2014). Cytidine and TAU have shown response rates of 53 to 55% in 
decreasing depressive symptoms in adults with bipolar disorder in previous clinical trials. 
However, in a placebo-controlled trial of cytidine as an adjunctive therapy to valproate, 
there was not a significant difference between cytidine and placebo response rates (53% 
vs. 47%) after 12 weeks of treatment (Yoon et al., 2009). 
 The placebo response in the present study was 50%, which is high but not 
uncommon. Placebo response in treatment trials for participants with bipolar disorder has 
proven to be a challenge, with the placebo response rate as high as 40 to 55% in 
randomized, double-blind, placebo-controlled trials for bipolar depression (Iovieno et al., 
2014). Furthermore, it is important to consider that up to 52% of antidepressant trials of 
bipolar depression and 40% of trials on bipolar mania fail to distinguish the active 
treatment from the placebo (Vieta & Carne, 2005).  
 It should be noted that 11 out of 20 participants with BD in the study were taking 
antidepressants, and 7 of these participants were in the uridine group. Taking 
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antidepressants alone as a treatment for bipolar depression is contraindicated, as 
antidepressants have been reported to increase irritability and switching to mania 
(McInemey & Kennedy, 2014). No participants with BD in the study switched to mania 
as evidenced by YMRS scores > 12; however, the use of antidepressant medications 
could have affected participant outcomes. Antidepressants increase the amount of 
serotonin in the brain and uridine is purported to increase brain dopamine. The interaction 
between brain dopamine and serotonin due to taking both uridine and antidepressants in 
individuals with bipolar disorder is unknown. More research is needed to evaluate the 
efficacy of uridine as a treatment for youth with bipolar depression. 
 
Neurocognitive Deficits in Bipolar Disorder 
         Attention was measured with the Conners Continuous Performance Test-Third 
Edition, (CPT-3). Participants with BD made more omission and commission errors, and 
were less able to detect the target from nontargets when compared to performance of the 
unaffected comparison group on the CPT-3. Additionally, participants with BD 
performed worse on executive functioning measures, including the Wisconsin Card 
Sorting Task, the Color Word Interference Test, and the Trail Making Number-Letter 
Switching Test, than the unaffected comparison group. Furthermore, participants with 
BD performed slower on processing speed tasks, the Coding and Symbol Search subtests 
from the WAIS-IV, when compared to the unaffected comparison group. 
         In summary, participants with BD revealed performance deficits in attention, 
executive functioning, and processing speed. Due to correction for multiple comparisons, 
no statistically significant differences were observed between bipolar youth and 
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unaffected comparisons. The current study did not have the power to show the robust 
effect of neuropsychological deficits for participants with bipolar disorder compared to 
unaffected comparison participants; however, differences were observed. 
        Deficits in these areas could be better explained by medications that the 
participants were taking (Henin et al., 2007). Additionally, all participants with BD were 
in a current state of depression, which could have further impaired neuropsychological 
functioning; however, there is evidence that neurocognitive deficits persist regardless of 
the mood state. An increase in attention and executive functioning performance with 
improvement of depressive symptoms could suggest that participants may be less 
impaired in these domains during euthymia or as symptoms of depression decrease. 
 
Effects of Uridine on Neurocognitive Performance 
 
 Both the uridine and placebo groups increased their attention and executive 
functioning performance from baseline to week 6. Results found no difference between 
the uridine and placebo groups in performance on any of the neuropsychological 
composites from pre- to posttreatment. While results from this study did not provide 
evidence for uridine as a neurocognitive enhancer, it did not appear to have a negative 
effect on cognition.  This is an important consideration, as many of the available 
treatments for adolescent bipolar depression can have a considerable negative impact on 
cognition.  
 Improved attentional performance has also been found with citicoline, a 
pyrimidine that breaks down into uridine and choline, in a study of healthy adult women 
and adolescent males (McGlade et al., 2015; McGlade et al., 2012).  
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Both of these studies found that with daily oral administration of citicoline, performance 
on the CPT-II improved; adult women made fewer omission and commission errors and 
adolescent males had improved detectability and lower commission errors.  
 Due to weight variation among participants in the citicoline study with adolescent 
males, dose by weight was calculated and used in the analyses (McGlade et al., 2015). In 
the current study, participants ranged in weight from 90 to 358 lbs. Furthermore, the 
participants that weighed the most and the least only differed by 1 year in age and grade 
level, yet had a difference in weight of 268 lbs. Therefore, participant weight and 
metabolism may have affected the dose and effectiveness of uridine for participants. 
 Results of the CPT-3 suggested that the mean performance of both groups of 
participants with BD improved during the study. Since participants with BD also had a 
mean overall decrease in depression, one possible explanation for these results is that a 
decrease in depressive symptoms resulted in improved attention performance. An 
alternative explanation for the improvement in attention performance may be due to 
practice effects. Participants may improve performance after exposure to the CPT-3 by 
decreasing omission and commission errors, and increasing detectability and variability 
due to prior testing. The same explanations can also be applied to the improvement in 
executive functioning performance of participants with BD.  
 While uridine may not have had a negative effect on cognition, it may have 
attenuated practice-induced learning with repeated exposure. Research has shown 
practice effects in healthy volunteers for the WCST across 12 months (Basso et al., 2001) 
and on the TMT across 3 weeks (Buck, Atkinson, & Ryan, 2008). The CPT-3 was 
assessed for test-rest reliability and practice effects at a 1-to 5-week interval. Results for 
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120 participants revealed that omission errors, perseveration errors and variability stayed 
consistent over time; however, detectability (cohen’s d = -.21) and commission errors  
(Cohen’s d = -.31) decreased at the second administration (Conners, 2014). 
 Results from the comparison group showed that neurocognitive performance from 
the baseline to 6 weeks later was relatively stable, except for the processing speed task. 
Participants in the comparison group showed significant improvement in processing 
speed performance following 6 weeks. Practice effects on WAIS-IV have been shown to 
occur in the Processing Speed Composite across 3- and 6-month intervals. A sample of 
54 participants with average intelligence improved approximately 9 points on the 
Processing Speed Composite at either interval (Estevis, Basso, & Combs, 2012). In 
contrast, participants with BD did not have the same improvement in processing speed, 
but showed improvement in other domains.  
 
Academic Experiences and Challenges With Bipolar Disorder 
  Youth with BD reported many difficulties and challenges academically. The 
majority of participants with BD had an interruption or discontinuation in education. 
Additionally, some participants received special education services or attended 
alternative classes, programs, or schools. Almost half of the participants with BD found 
that transferring to a new program, school, or college was helpful.  
 Even though participants with BD experienced challenges and academic 
difficulties, most of the participants with BD were high-achieving students and had 
educational goals that they strived to accomplish, much like the unaffected comparison 
participants. Only 2 of the participants with BD had discontinued school and had been 
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unable to return, but still had intentions of attending in the future.  
 Most of the participants with BD did not report experiencing persistent academic 
difficulties (e.g., in reading or math). In fact, only a quarter of the participants qualified 
for special education services and many of them received services for emotional and 
behavioral difficulties. Additionally, 2 of the students that were attending alternative 
classes or schools were doing so for social/emotional reasons. Many of the participants 
reported that symptoms of depression and mania had a huge impact on their academic 
and/or occupational functioning (e.g., difficulty concentrating, lassitude, fatigue, 
psychomotor retardation, distractibility, racing thoughts, irritability, pressured speech, 
restlessness). Furthermore, once a mood episode worsened, many participants reported 
they often were not able to continue attending school or keep up with assignments and 
homework. Participants with BD reported the most academic difficulties during a severe 
depressive episode.  
 
Association Between Neurocognitive Deficits and Academic Experiences in BD 
 
 There was an association between academic difficulties and neurocognitive 
performance for participants with BD on attention, working memory, executive 
functioning, and processing speed. Participants with BD who received special education 
services had lower attention, working memory, executive functioning, and processing 
speed performance. 
 Since neurocognitive deficits have been known to persist despite mood episodes, 
these deficits may affect how students are able to plan, learn, socialize, and function 
academically. Students with BD who have neuropsychological deficits that impair 
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academic performance may require an individualized education program and specialized 
instruction in order to be successful at school. 
 It is important to consider that much of the cognitive testing that goes into 
qualification for special education services includes measurement in the areas of 
attention, working memory, executive functioning, and processing speed as part of the 
assessment process. Therefore, if students perform poorly in those areas, it may impact 
whether or not they qualify for special education services; however, most of the 
participants with BD who reported receiving special education services noted that they 
did so for emotional and behavioral difficulties. Participants were most likely referred or 
identified, and qualified for specialized education services based on emotional and 
behavioral needs, and academic testing may not have been the focus of eligibility. In fact, 
only 1 participant with BD reported having an IEP for math.  
BD participants who had more attention, working memory, and processing speed 
deficits self-reported experiencing academic difficulties specific to classes and mood 
episodes, and also centered on symptoms involved in mood episodes. Participants 
reported difficulty with a certain course, specific teacher, lots of homework, or a project 
assigned. Additionally, participants stated that once a mood episode began, they were 
unable to continue attending school, keep up with assignments, or complete homework. 
Participants did not report academic difficulty with reading, writing, or math that 
persisted over time. Many participants stated that they had difficulty with certain 
symptoms of BD that impacted academic performance. For participants who experienced 
extreme mood symptoms/episodes that had an impact on school attendance and learning, 
it was apparent that 504 accommodations could benefit them during these episodes. 
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 This study did not find the same rates of reading, writing, and math difficulties 
that have previously been reported in youth with BD, especially those with 
neuropsychological deficits (Pavuluri, O'Connor, et al., 2006). The majority of the 
participants reported that their academic difficulties were not persistent; rather they 
occasionally failed a course, dropped out of a program, transferred to a new school, or 
had to retake an entire semester. This may be due to the fact that a higher functioning 
group of participants with BD with higher cognitive ability were enrolled in the study.   
   There was an association of lower processing speed performance with enrollment 
in alternative classes or schools for participants with BD. Additionally, lower processing 
speed performance was associated with transferring to different classes, programs, and 
schools. It is not surprising that participants with BD who have processing speed deficits 
have transferred to alternative programs or new schools to complete their classes. In a 15-
year follow-up study, processing speed deficits in participants with BD were strongly 
associated with decreased social and global functioning (Burdick et al., 2010). Almost 
half of the participants with BD reported transferring to a new environment due to social 
or academic difficulties. These participants may feel more comfortable in alternative 
educational settings or transfer to programs or universities that are a better fit for them.  
Bipolar participants who had an ADHD diagnosis had lower working memory 
scores. Working memory tasks required the recall of digits forward, backward, and 
arranging digits in mental order and then mentally ordering sequences of letters and 
numbers. Participants with ADHD had significant deficits recalling numbers backwards. 
Thirty percent of the bipolar participants were diagnosed with ADHD and half of those 
participants were already taking medication for ADHD.  Since participants with ADHD 
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did not have deficits in any domains other than memory, one explanation for these results 
is that medications for ADHD may have improved performance on attention and other 
neurocognitive tasks.  
As performance on the WASI-II increased, so did performance on attention, 
working memory, executive functioning, and processing speed tasks. Participants with 
the highest WASI-II scores did not experience deficits in baseline neuropsychological 
performance compared to unaffected controls. Bipolar participants who performed higher 
cognitively and neuropsychologically than other participants also appeared to have a high 
range of functioning. Many of these participants were attending college and working, and 
had social relationships. Surprisingly, participants with the highest WASI-II scores also 
had the most severe depression scores and the most extreme histories of hospitalizations. 
It appeared when these participants experienced extreme mood episodes, they reported 
interruption and significant impairment in many if not all areas of functioning (e.g., 
social, academic, and occupational). Additionally, these participants had serious histories 
of suicidal ideation and past suicide attempts. 
 
Safety and Tolerability 
 There were no serious adverse events that took place during the study and 
participants did not report a significant number of adverse events. As shown in Table 14, 
participants in the uridine group reported more adverse events than those in the placebo 
group, but 35.7% of those events were related to the treatment. There were several other 
adverse events reported such as headaches, nosebleeds, and respiratory infections; 
however, these were unrelated to the treatment. There were a greater number of subjects  
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Table 14. Summary of Adverse Events for Participants. 
________________________________________________________________________ 
 
Uridine Group           Placebo Group 
      (N = 9)                       (N = 8) 
________________________________________________________________________ 
Number of Adverse Events Reported            14            9   
Number of Subjects with Adverse Events [1]           8            5 
 
Number of Adverse Events by Relatedness to Treatment* 
 
    Unrelated (Percentage)                    9 (61.5%)               7 (77.8%)     
     Related  (Percentage)          5 (35.7%)    2 (22.2%)  
______________________________________________________________________________________ 
 
[1] Subjects who experience one or more adverse events are counted only once 
* Percentages are based on number of adverse events reported for each treatment group 
 
in the uridine than the placebo group that reported adverse events. 
 The most reported events for the uridine group were classified as gastrointestinal, 
which are known side effects of uridine. These events included upset stomach, vomiting, 
nausea, etc.  Table 15 provides a classification of events by body system. These results 
suggest that participants safely tolerated treatment with uridine and there were no severe 
adverse events during the study.  
 
Limitations and Future Considerations 
           Participant medications were not controlled for during the study, and this was a 
significant limitation of the study. Participants in the uridine and placebo group took 
different medications, including mood stabilizers, antidepressants, anti-anxiety  
medications, and medication for ADHD.  Mood stabilizers, antidepressants, 
antipsychotics, and medications for anxiety could have a negative effect on depressive 
symptoms and neurocognitive test performance. In addition, certain medications could 
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Table 15. Adverse Events by Body System for Participants 
* Percentages are based on number of AE reported for each treatment group. 
 AE: Adverse Event; HEENT: Head, eyes, ears, nose, and throat   
 
have improved BD participants’ cognitive test performance. For example, there were 6 
participants taking lamotrigine, which has shown to increase working memory and verbal 
memory in adolescents with bipolar disorder after 14 weeks of treatment (Pavuluri et al., 
2010). Additionally, there were 6 participants with ADHD, 3 of whom were taking 
medication for ADHD that may have improved participant performance on attention and 
other tasks. It would be critical to control for the use of medications in future studies of 
uridine in depressed participants with BD, especially the use of antidepressant 
mediations.  
            The small sample size significantly limits the findings of the study. Three 
participants were removed from the sample and 1 chose not to participate, which made 
the sample size even smaller.  A larger sample size would improve statistical power and
  System      Number of AEs*                  Subjects with AEs 
 Uridine Placebo Uridine Placebo 
Constitutional 0 (0.0%) 1 (11.1%) 0 (0.0%) 1 (12.5%) 
Hematologic 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Endocrine 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Psychiatric 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Cardiovascular 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Genitourinary 1 (7.1%) 0 (0.0%) 1 (9.1%) 0 (0.0%) 
Respiratory 2 (14.3%) 2 (22.2%) 2 (18.2%) 2 (25.0%) 
Neurological 2 (14.3%) 4 (44.4%) 1 (9.1%) 3 (37.5%) 
Gastrointestinal 5 (35.7%) 2 (22.2%) 5 (45.5%) 2 (25.0%) 
Integumentary 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Musculoskeletal 1 (7.1%) 0 (0.0%) 1 (9.1%) 0 (0.0%) 
HEENT 3 (21.4%) 0 (0.0%) 2 (18.2%) 0 (0.0%) 
Overall              14               9                 
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increased generalizability. In particular, research is needed with larger participant pools 
at multiple locations to increase generalizability. In order to detect robust findings, a 
larger sample size would have been preferred. Another limitation to this study is the 
design, which may not have been sensitive to effects of the treatment and may not have 
accurately captured the biggest effect of uridine on depressive symptoms or 
neurocognitive performance. Rapid responses to pyrimidines to treat depression have 
been reported by Jensen et al. (2008) and Yoon et al. (2009). Jensen et al. (2008) reported 
a rapid-onset of treatment response to TAU within 4 weeks in a study of depressed rapid 
response following administration of cytidine as an adjunctive treatment to valproate 
during weeks 1 to 4 in bipolar depression throughout a 12-week trial.  
 To address potential problems with the study design, neuropsychological testing 
could be performed earlier in the study following 2 and 4 weeks of uridine 
administration. Neuropsychological performance could also be paired with another 
objective measure to increase the validity of results. For instance, neurocognitive testing 
could be performed in conjunction with functional magnetic resonance imaging (fMRI) 
and magnetic resonance spectroscopy (MRS). Thus, participant neurocognitive 
performance could be analyzed with fMRI and MRS results to see if changes in the brain 
metabolites or blood flow are associated with changes in performance on neurocognitive 
tasks. Finally, future studies of uridine may benefit by shortening the length of the 
administration to 4 weeks and by focusing on repeated measurement during weeks 1 to 4. 
 Uridine levels have shown to be highest in the body for 2 hours after taking 
uridine orally. For participants who took study medication the morning prior to 
neuropsychological testing, uridine might have still been present in their bodies. For other 
subjects, the effect of uridine may not have lasted during neuropsychological testing. 
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Weight and metabolism of the participant could have also affected the how long the 
uridine stayed in the body/brain. Future studies might consider dosing participants with 
uridine based on their height and weight.  
Additional changes to the design to decrease the effect of placebo response would 
be an especially important area of future research. Due to the difficulty in differentiating 
a treatment response in individuals with bipolar disorder, the use of placebo has been 
regarded as having a very important (yet complex) role in affective disorders research. 
Variables found to be associated with greater response to placebo in bipolar disorder 
trials include whether the person is in a mixed episode or first episode, whether he/she 
has rapid cycling; and whether the study employs a fixed-dose design (Vieta & Carne, 
2005). Nierenberg et al. (2015) found that longer clinical trials and more severe illness 
reported at baseline also increased the risk of participants with BD responding to the 
placebo in randomized, double-blind treatment trials. These may be important variables 
to consider with placebo-controlled treatment trials for bipolar adolescents.  
 Participant adherence was another limitation of the study. It is unknown whether 
participants were actually taking study medication throughout the study. Even though 
participants and their parents reported taking the medication, it was not actually observed 
by the PI or Dr. Kondo. Furthermore, the only physical proof of treatment integrity in the 
study was participants keeping a medication log, bringing back unused medication to 
each weekly visit, and having it counted and recorded by staff. Future studies might 
employ medication dispensers that electronically record each time the study medication 
bottle is opened by the participant. This would dramatically increase future study costs, 
but it may also increase participant adherence and treatment integrity. 
            All mood measures and academic information were based on participant report. 
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This is a limitation, as many of the participants reported mood symptoms at the time of 
the study visit and may not have accurately reported for mood symptoms throughout the 
week. Future studies may consider use of electronic self-monitoring of mood throughout 
the study to help participants monitor bipolar symptoms frequently, which can be easily 
quantified to summarize symptoms throughout the week. These electronic mood trackers 
have been used in adult and adolescent studies of depression and bipolar disorder and 
technology in the form of applications on mobile phones and tablets, which are popular 
among youth.  
    The exclusion criterion of current substance use disorder may have led to a group 
of participants that were higher functioning academically and were exclusively in school 
or working. This may have implications for restriction in range of performance, and the 
neuropsychological domains may not be representative of the larger population of youth 
with BD. Specifically, substance use in BD is common and many youth with BD have 
reported using substances to cope with feelings and self-medicate. In fact, as high as 31% 
of youth with BD have been reported to have a comorbid substance use diagnosis (Frias, 
Palma, & Farriols, 2015). Substance use in adolescence is commonly associated with 
lower academic achievement and legal problems. Furthermore, use of substances over 
long periods has been associated with lower neuropsychological performance (Squeglia, 
Jacobus, & Tapert, 2009). Heavy alcohol use during adolescence can also decrease 
performance on memory, attention, spatial skills, and executive functioning. 
    Another limitation was the timing of the study, resulting in the inability to collect 
academic data. During the time period of the study, approximately half of the participants 
were enrolled during summer or when school was not in session. Additionally, 3 
participants with BD and 6 participants were not attending school during the study. 
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Therefore, comparisons could not be made with regard to academic performance. Future 
studies might consider recruiting participants from a school district and collaborating 
with a school psychologists, teachers, and administrators to collect a variety of different 
types of academic data, including grades, questionnaires, or historical academic data.  
 Most of the participants with BD were able and willing to complete the testing; 
however, the amount of motivation and effort that participants put forth differed. Many of 
the participants were eager at the baseline visit to perform well and appeared to be highly 
motivated. After being exposed to all of the measures during the baseline, the tests were 
no longer novel and some of the participants with BD did not put forth the same amount 
of effort at the final visit. During the final administration of tests, many bipolar 
participants were not motivated and a few struggled to complete some of the tests, 
especially the CPT-3. At the final visit, one bipolar participant reported worry that the 
CPT-3 interval would never end and felt “trapped inside of it”. Another participant stated 
upon completion of the CPT-3 at the final visit, that they would not return for another 
visit if they had to complete that test again. Both of these participants were in the uridine 
group. The level of effort and motivation by participants on testing, especially 
participants who struggled with testing was certainly a limitation of the study. 
The level of involvement of participants and their families was tremendous; 
however, the time commitment may have led to increased investment and motivation, 
which is another limitation. Participants and their families came to the study participated 
in the informed consent process and were fully aware of the time and travel necessary to 
participate in the study. Several participants drove over 100 miles round-trip weekly to 
participate in the study for 6 weeks. The level of parent support/involvement in the study 
certainly had an effect on adolescent participants. Parents transported adolescents to the 
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visits, attended appointments, and discussed weekly changes in their child’s mood.  They 
coordinated appointments and helped the participants complete the study. This level of 
parent attention and support could be an alternate explanation for decrease in depression 
scores. Participants and their parents were highly motivated and desperately wanted to 
get better, were dedicated to the study, and were committed to improving regardless of 
whether they were assigned to the placebo or uridine condition.   
 
Conclusion 
Data from this study indicate that more research is needed regarding uridine as a 
treatment for depression in bipolar disorder. Three participants in the uridine group 
showed a treatment response, as did 4 participants in the placebo group. Uridine did not 
have any negative effects on neurocognitive performance, but it did not prove to have any 
benefits solely for the uridine group. Furthermore, there were no significant differences in 
neurocognitive performance between either the uridine or placebo groups, although 
participants with BD showed more impairment in attention, executive functioning, and 
processing speed than unaffected comparison participants. Academic experiences for 
participants with BD were different from comparison participants and included more 
academic difficulties, discontinuations, and transfers to new schools, programs, and 
classes. Participants who reported academic difficulties or received special education 
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